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ABSTRACT 
The interaction of Nerve Growth Factor (NGF) with the high affinity 
receptor, trk, and the low affinity receptor, p75, has, been investigated. Peptide 
fragments of NGF have been chemically synthesised by Solid Phase Peptide 
Synthesis Techniques. Separate biological assays for each of the receptors have been 
set up by our collaborators at Parke Davis. These assays test the ability of the 
synthesised peptide fragments to inhibit NGF binding to the receptor. In this way, 
potential binding sites of NGF to each of the receptors have been identified. 
Work previously carried Out in this laboratory led to the identification of a C-
terminal region of NGF as a receptor binding domain for the p75 receptor. The 
synthesis of analogues has highlighted the importance of certain N-terminal residues 
of this C-terminal fragment, for binding to the low affinity receptor. The 
identification of a potential secondary binding site to this receptor was made by 
linking three positively charged residues, believed to form a positively charged 
complex for binding to the receptor, to the previously identified C-terminal 
fragment. An eleven carbon chain linker, aminoundecanoic acid, was used for this 
purpose. It was also found that a dimer of this C-terminal region bound with higher 
affinity than did the monomer. 
Preliminary results have indicated that the C-terminus of NGF is important 
for binding to the high affinity receptor also. These peptides have been shown to 
bind competitively with NGF to the high affinity receptor i.e. the question of 
whether these peptides inhibit NGF binding to the receptor by binding to the receptor 
themselves or simply by binding to NGF, has been answered. This indicates that 
these peptides could act as potential agonists for NGF. 
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CHAPTER ONE: INTRODUCTION 
1.1 ALZHEIMER'S DISEASE 
1.1.1 Introduction 
Alzheimer's Disease (AD) is a form of senile dementia which affects about 
10 percent of people in their seventies and 30 percent in their eighties. It is the fourth 
major cause of death after heart disease, cancer and stroke. The dramatic rise in life 
expectancy during this century has enabled many more to reach an age at which 
degenerative diseases of the brain become common. Associated with Alzheimer's 
Disease is a loss of memory, judgement and emotional stability which usually leads 
to death in a severely debilitated state between four and twelve years after onset. The 
total number of sufferers is about 500,000 in the U.K. 400,000 in France and four 
million in the U.S. The annual cost is estimated at more than $80 billion in the U.S., 
primarily for custodial care. At the present time there is no cure for this harrowing 
disease and there is limited treatment for retarding the progression of the disease. 
1.1.2 Alzheimer's Disease Pathology 
Alzheimer's Disease may only be diagnosed with certainty by close 
examination of the brain tissue. The characteristic pathological hallmarks are large 
numbers of amyloid plaques surrounded by neurons containing neurofibrillary 
tangles('), vascular damage from extensive plaque deposition( 2) and neuronal cell 
lossW. Amyloid is a generic description applied to a heterogeneous class of tissue 
protein precipitates that have the common feature of 3-pleated sheet secondary 
structure(3). The main constituent of cerebral amyloid of Alzheimer's Disease has 
been shown by Glenner and Wong( 4) to be a 39-42 amino acid polypeptide, 
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designated P/A4  which is derived from a 695-770 amino acid precursor known as 
amyloid precursor protein (APP). This protein has a single transmembrane 
domain(5-8) and is encoded by a gene located on chromosome 21. The physiological 
role of APP is currently unknown. The puzzling thing about the formation of 3/A4 
from APP is that normal proteolytic cleavage of APP results in cleavage occurring 
within the 3/A4 domain(910 . Thus, the major processing/secretion pathway for APP 
cannot be associated with the release of /A4. However, it is widely believed that 
deposition of /A4 is the causative agent of Alzheimer's pathology and that the 
neurofibrillary tangles, cell loss, vascular damage and dementia follow as a direct 
result of this deposition(" ) .  
There are different forms of Alzheimer's Disease, one of these being what is 
termed familial Alzheimer's Disease. This form of the disease generally affects 
people at an earlier age than the sporadic form. In many cases of familial 
Alzheimer's Disease a mutation in the APP gene at codon 717 has been identified( 12). 
This mutation has been detected in English, American and Japanese families with 
early onset Alzheimer's Disease( 13). It is unclear how these mutations cause amyloid 
deposition but it has been proposed that they may inhibit the breakdown of a COOH-
terminal fragment of APP that contains 13/A 4 ( 12" 3). Several studies suggest that APP 
can also be processed by the endosomal-lysosomal pathway. This pathway of APP 
processing can lead to carboxy-terminal fragments of APP containing the entire /A4 
sequence( 14 " 5) and may eventually lead to /A4 deposition (see Fig. 1.1). 
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1.1.3 Cholinergic Deficits in Alzheimer's Disease 
Many neuronal populations are found to degenerate in the brains of 
Alzheimer's patients. Those which have attracted most interest are the cholinergic 
neurons of the basal forebrain. Nerve cells interact with other nerve cells at junctions 
which are called synapses. Communication across the synapse is carried by small 
chemical molecules called neurotransmitters. One such neurotransmitter is 
acetylcholine. Acetylcholine was the first neurotransmitter to be discovered. It is 
synthesised by the transfer of an acetyl group from acetyl CoA to choline (Fig. 1.3). 
The reaction is catalysed by choline acetyltransferase. The synthesised acetylcholine 
is stored in synaptic vesicles at the end of the presynaptic axon. On arrival of a nerve 
impulse, acetylcholine is released into the synapse (Fig.1.2). Diffusion across the 
synapse to the postsynaptic membrane occurs, and the acetylcholine molecules 
combine with specific receptor molecules. Excess acetylcholine is broken down to 
acetic acid and choline by the enzyme acetylcholinesterase. 
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Fig.1.2 Diagrammatic representation of the cholinergic synapse 
Acetylcholine 
Fig.1.3 Mechanism of synthesis and breakdown of acetylcholine 
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In the central nervous system, cholinergic neurons of the basal forebrain 
extend to regions such as the cortex and the hippocampus (Fig. 1.4a). In Alzheimer's 
Disease the activity of choline acetyltransferase (a marker for cholinergic neurons) is 
considerably reduced in these areas. The finding that neurons of the basal forebrain 
undergo selective degeneration in Alzheimer patients has led to the belief that the 
reduction of choline acetyltransferase activity in the cortex and hippocampus is a 
direct result of degeneration of these cholinergic neurons of the basal forebrain( 16 ' 17 
(See Fig.1.4a). Levels of post-mortem neocortical choline acetyl transferase have 
been shown to correlate with severity of mental dysfunction( 18). This is believed to 
be an important factor in Alzheimer's Disease and as a result, many current drug 
strategies are based on increasing cholinergic function in the central nervous system. 
At present the only drug on the market for treating Alzheimer's Disease on this basis 
is Tacrine (Fig. 1 .4b). Tacrine is an acetylcholinesterase inhibitor( 19 . Inhibition of 
this enzyme obviously increases the level of acetylcholine in the brain. Other drugs 
with similar effects are also being studied but none 'LS without unpleasant side 
effects and as yet none of these drugs haS amounted to a cure. In fact, it is found 
that the effects diminish with time and after a year or two the relentless decline of 
Alzheimer's Disease continues. 
More recently, investigations in to the treatment of Alzheimer's Disease has 
led to the targeting of cholinergic neurons in a different way. Instead of 
compensating for the loss of cholinergic neurons by replacing the subsequent loss of 
acetylcholine levels, scientific investigation into keeping the neurons alive in the first 
place is being carried out. One obvious target for this purpose is the use of 
neurotrophic factors( 20), proteins which promote the maintenance, growth and 
functional performances of neuronal populations. 
5 
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Fig.1.4 a. Cholinergic nerve tracts of the basal forebrain 
b. Structure of Tacrine, used in the treatment of Alzheimer's Disease. 
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1.2 NERVE GROWTH FACTOR 
1.2.1 NGF - A Member of the Neurotrophin Family 
Nerve Growth Factor (NGF) was originally discovered in the early 1950's by 
Rita Levi-Montalcini of Washington University School of Medicine( 21 ). It was found 
that NGF was required in the peripheral nervous system for the development and 
maintenance of sympathetic nerve cells that use catecholamine neurotransmitters 
such as norepinephrine and dopamine. The search for NGF action in the central 
nervous system was initially concentrated on catecholamine-producing neurons in 
the brain. No apparent effects of NGF on catecholaminergic neurons in the brain 
could be found and it was therefore assumed that NGF did not act in the central 
nervous system at all. However, in the mid-1980's evidence came to light that NGF 
did have a role in the central nervous system. It was discovered that NGF increased 
the choline acetyltransferase activity in the basal forebrain, hippocampus and 
neocortex, of neonatal rats( 22). 
NGF is a member of a group of proteins called neurotrophic factors. 
Neurotrophic factors are proteins that are capable of stimulating survival and growth 
of nerve cells. Several protein families have neurotrophic factor members. For 
example, fibroblast growth factors( 23), polypeptides involved in various biological 
activities in vivo and in vitro, and epidermal growth. factor( 24) which stimulate the 
growth of epidermal and epithelial cells. NGF belongs to the protein family called 
neurotrophins. The other known neurotrophins are brain-derived neurotrophic factor 
(BDNF)(25 .26), neurorrophin-3 (NT-3)( 27), neurotrophin-4 (NT-4)(28) and 
neurotrophin-5 (NT-5)( 29). The individual neurotrophins are highly conserved among 
mammalian species and share approximately 50% of the amino acids with other 
members of this group (Fig. 1.5). NGF is the best characterised member of the group. 
7 
1 	 26 	 50 
inNGF SSTHPVFHMGEFSVCDSVSVWV - - GDKTFAT D I KGKEVT V LAEVN I NN SVF RQYFFET KCRAS NPV 
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79 	 100 
mNGF ESGCRGIDSKHWN SYCflTHTFVKAL1TDEKQ-AA WRF IRIDTACVCVLSRKATR 
hNGF DSGCRGIDSKHWN SYCTITHTFVKALTMDGKQ-AAWRF IRIDTACVCVLSRKAVRRA 
BDNF KEGCRGIDKRHWNSQCRTFQSYVRALTMDSKKRIG WRF IRIDTS CVCTLTIKRGR 
NT-3 	KNGCRGIDDKHWNSQCKTSQTYVRALTSENNKLVGWRWIRIDTS CVCALSRKIGRT 
Fig. 1.5 Sequence alignment of NGF and related sequences 
NGF protein has been purified and sequenced from the submandibular gland 
of the male mouse(30 '31 ). It is synthesised as a 305 amino acid protein prepro-NGF. 
Prepro-NGF is a complex of three types of subunit, cx, 0 , and 'y.(32)  The y subunit is a 
trypsin-like protease( 33), the cc subunit is a protease inhibitor which is thought to 
protect NGF from proteloysis( 34). The biologically active NGF is represented by the 
subunit. Proteolytic cleavage of the complex releases the mature -NGF protein 
which is a basic 118 amino acid protein (120 in human NGF) and forms a non 
covalent dimer( 35). 
The crystal structure of p3-mouse NOF has been determined( 36). This shows it 
consists of seven a-strands forming three anti-parallel pairs. The residues which 
contribute mainly to this structure are well conserved among the neurotrophins 
giving reason to believe that the other neurotrophins share the revealed NGF 
structure. 
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Fig.1.6 Deductions from the crystal structure of mNGF 
1.2.2 NGF Receptors p75 and Trk 
There are two known receptors which bind NGF. The first one to be 
discovered was the low affinity NGF receptor (LNGFR)( 37). This receptor binds NGF 
with nanomolar affinity. It is a cysteine-rich glycoprotein which contains 
approximately four hundred amino acids in a single peptide chain. It has a single 
membrane-spanning domain separating a slightly longer extracellular domain from a 
shorter cytoplasmic domain 38 . It has been named p75 NGFR based on the 
approximate molecular weight of the human receptor of 75000. The extracellular 
domain contains four cysteine-rich loop regions (Fig. 1.7). Each of these loops 
contains six cysteine residues and it is generally assumed that these cysteines form 
three disulphide bridges within the loop. These cysteine-rich regions are highly 
conserved among the species and it is now known that these loops determine the 
NGF binding domain 40 . Each of the loops is required and they are arranged in the 
correct order to create the binding site of NGF( 4142 . The short cytoplasmic domain 
does not contain distinctive motifs but it has been suggested that the conserved C-
terminal of p75 may have a G protein linked signal transduction mechanism. 
However, this has yet to be determined 43 . It should be noted that p75 binds all the 
neurotronhins with similar affi n i ty 4446 . 
Fig. 1.7 Four internal repeats in p75 
The identification of a second NGF receptor, which binds NOF with 
picomolar affinity, was made by Martin-Zanca et al when they noticed that the 
distribution of the product of the proto-oncogene trk was restricted to targets of NGF 
action in neural crest derived sensory neurons 47 . Meakin and Shooter subsequently 
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reported that high affinity NGF receptors could be immunoprecipitated with 
anti-phosphotyrosine antibodies suggesting that the high affinity NGF receptor 
(HNGFR) contains tyrosine kinase activity 48). This proved to be true when it was 
found that the tyrosine kinase activity and autophosphorylation of trk was stimulated 
on binding of NGF(4950). This tyrosine kinase receptor is a part of a family of 
tyrosine kinases, the other members of which have been named as trk B(51 ) and trk 
C(52). These proteins, which have a molecular weight of approximately 140,000, have 
been found to bind preferentially to the neurotrophins BDNF and NT-3 respectively 
but not to NGF(5357). The kinase domains of trk, trk B and rrk C share approximately 
85% sequence homology while there is approximately 50% homology among the 
extracellular domains. The extracelluar domains contain three leucine-rich repeats of 
24 amino acids containing 8 leucines which are bounded by two clusters of cysteine 
residues. There are also two immunoglobulin-like C 2 repeats in the extracellular 
domain (Fig. 1.8). These features give rise to the possibility of potential protein 
protein interactions or cell adhesion characteristics of the rrk receptors. 
Cysicine Cluster # I 
Leucine Motif 
Cysteinc Cluster # 2 	' 
lgG-C2 -E Domain 








Fig. 1.8 Structure of NGF receptors. 
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1.2.3 The Molecular Nature of the High Affinity Binding Receptor 
As stated earlier, NGF plays an important role in the development and 
maintenance of neurons in both the peripheral and the central nervous systems. In the 
peripheral nervous system it is noted for its ability to stimulate the growth of 
sympathetic and sensory neurons. The role of NGF in the central nervous system 
when investigated by Mobley (22)  revealed that intracerebroventricular injections of 
NGF increased choline acetyltransferase activity in the basal forebrain, hippocampus 
and neocortex of neonatal rats. The hippocampus and cortex are terminal regions for 
the fibres of basal forebrain cholinergic neurons. This was supported by the later 
observation that NGF binding sites in the basal forebrain correspond to the location 
of cholinergic neurons(58-60). 
NGF is produced by the target tissues of the cholinergic basal forebrain 
neurons in the central nervous system. Binding of the growth factor to receptors on 
the nerve terminals occurs, followed by rapid internalisation of the NGF:receptor 
complex(61). NGF is then retrogradely transported to the perikaryon (cell body) in the 
septum(62). This results in the delivery of biologically active NGF to the cell body 
but the mechanism of signal transduction is as yet unknown. 
A number of questions are still unanswered about the mechanism of action of 
NGF. Firstly, there is much debate about the molecular nature of the receptor which 
binds NOF with high affinity. A number of cell lines expressing either one or both of 
the NGF receptors have been developed, in order to study the effects of NGF binding 
to each of the receptors. The most widely used cell line is a noradrenergic clonal line 
of rat adrenal pheochromocytoma, PC12 cells( 63). PCI2 cells do not require NGF for 
their growth and survival, however in the presence of this factor the cells respond by 
shifting from a chromaffin-like cell to one with neurites that resemble a sympathetic 
neuron(64). These cells express both p75 and trk receptors. Biological responses to 
NGF are only observed in the presence of high affinity binding. No biological 
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responses mediated solely by the low affinity receptor have been observed. It has 
been suggested that co-expression of rrk and p75 c5 required for the formation of 
high affinity NGF binding sites 65 . The proposal is that these proteins form a 
heterodimer which binds NGF (Fig.1.9a). This model was primarily based on 
binding studies in which the formation of high affinity NGF binding sites in 
heterologous COS cells required coexpression of p75 and rrk. Additionally, high 
affinity binding was found to require both cytoplasmic and extracellular NGF 
binding domains of p75(66). On the contrary, it has also been reported that a 
percentage of trk receptors can bind NGF with high affinity in the physiological 
picomolar range(67). Also, coexpression of equal numbers of p75 and trk receptors 
did not appear to affect the dissociation constant or the relative percentage of low 
and high NGF binding sites displayed by the trk receptors. Cross-linking studies in 
cells expressing both receptors have revealed the existence of both p75 and trk 
homodimers (Fig.1.9b) but p75-trk heterodimers were not found(68). Other studies 
have also contradicted the idea of a heterodimeric receptor. For example, it has been 
reported by Weskamp and Reichardt( 69) that polyclonal antibodies which were 
capable of inhibiting NGF binding to p75 receptors in PC12 cells did not eliminate 
the high affinity receptors or their responsiveness to NGF. Ibanez et al(70) have 
reported that a mutated form of NGF which binds to trk but not to p75 receptors, 
retains much of it's biological activity. Meakin and Shooter') reported that three 
antibodies directed against different epitopes on the low affinity NGF receptor did 
not recognise the high affinity receptor subtype. Presumably if p75 was associated 
with the high affinity receptor, these antibodies would recognise the high affinity 
receptor also. Studies carried out using tyrosine kinase deficient mutants of trk 
showed that coexpression of these mutants with wild type rrk receptors resulted in a 
significant inhibition of NGF mediated signal transduction. This indicated that the 
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Fig. 1.9 Proposed mechanisms for high affinity NGF binding. 
Heterodimer between p75 and trk binds NGF. 
Homodimers of p75 and trk bind NGF separately. 
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1.2.4 Function of the NGF Receptors p75 And Trk 
The interaction of NGF with the receptors initiates signal transduction events 
that are key to the mechanism of action of NGF. It is not clear whether signal 
transduction occurs only at the level of the nerve terminal membrane or if it also 
occurs during the transport of the NGF:receptor complex. The high affinity receptor, 
irk, is a tyrosine kinase which has been demonstrated to undergo 
autophosphorylation on binding of NGF( 490). It has been shown that the kinase 
activity may be blocked by 5'-S-methyladenosine. This inhibitor also blocks NGF-
induced differentiation of PC12 cells but does not affect NGF binding to its 
receptors(72). These findings confirmed previous suggestions that activation of the 
NGF receptor complex results in tyrosine phosphorylation 48). In addition, it was 
found that a mutant PC12 cell which lacks significant levels of trk and is non 
responsive to NGF, restores its biological response to NGF when a trk cDNA is 
introduced(73). There can be no doubt, therefore, Of the importance of this receptor 
for signal transduction when bound by NGF. 
The function of the low affinity receptor, p75, is less clear however. As 
explained earlier, this receptor may have a domain resembling mastoparan which 
raises the possibility that the receptor may interact with a G protein as part of a 
signal transduction mechanism 43). However, this suggestion has been made based on 
the predicted tertiary structure analysis of p75 and it has yet to be determined. Other 
functions have been suggested for p75. It may act as a presentation receptor which 
concentrates NGF(74). There is also some evidence to indicate that it may be involved 
in the retrograde transport of NGF( 75), or it may aid in discriminating among 
neurotrophic factors 76). This low affinity receptor belongs to a family of diverse cell 
surface proteins including two tumour necrosis factor receptors, the Fas antigen, the 
T cell antigens 0X40 and mu4-1BB and the B cell antigen CD40. This family of 
proteins has a high degree of homology in the cysteine-rich repeats in the 
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extracellular domain. Rabizadeh et al 77) have reported that expression of p75 
induced neural cell death when p75 was unbound but binding by NGF or monoclonal 
antibody inhibited cell death induced by p75. It is possible, therefore, that the 
function of NGF binding to p75 is to inhibit this process known as apoptosis. 
Interestingly, another member of this receptor family, the Fas antigen, has been 
shown to induce apoptosis in murine cells which were transformed with the Fas 
antigen cDNA(78). 
It is clear, therefore, that two separate receptors exist for NGF in responsive 
cells. The role of the trk receptor in neurotrophin function is more clearly defined 
and understood than that of the p75 receptor. For a review of neurotrophin receptors 
the reader is referred to reference 20. 
1.2.5 NGF and Alzheimer's Disease 
Several studies have been carried Out to investigate the effect of NGF 
treatment on cholinergic neurons in the central nervous system. NGF receptors p75 
and trk are selectively expressed by forebrain cholinergic neurons 79). Early studies 
revealed that NGF injected into the hippocampus and cortex was taken up by 
cholinergic afferents and transported back to the cell bodies in the basal 
forebrain(80 ' 81 . In support of the hypothesis that NGF acts selectively on cholinergic 
neurons as a target derived signal, NGF protein levels as well as mRNA coding for 
NGF are highest in hippocampus and cortex and hippocampal target cells of the 
cholinergic neurons express NGF mRNA 8286). 
The effect of NGF treatment on the maintenance of cholinergic neurons has 
been investigated in animals by severing cholinergic projections from the basal 
forebrain and examining the effect of NOF treatment on these lesioned neurons. It 
has been found that infusion of NOF can rescue the cholinergic neurons, stimulate 
axonal growth and improve cholinergic function( 8789 . These ascending cholinergic 
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projections undergo severe degeneration in Alzheimer's Disease( 90 '91) and there is 
strong evidence to suggest that the degeneration of the neurons is directly related to 
the memory and cognitive dysfunction suffered by these patients( 92). Therefore, it has 
been proposed that NGF treatment may be beneficial to Alzheimer patients. 
Nerve Growth Factor is a large protein which will not cross the blood-brain 
barrier. This is a problem which will have to be overcome in order to be able to use 
NGF as a therapeutic agent in Alzheimer's Disease. Several methods of NGF 
administration have been proposed 93 . The first method involves intracerebral NGF 
infusion. This method has been tried clinically both in Parkinsons and Alzheimer 
patients(94). The invasiveness of this procedure however makes treatment of this 
nature undesirable. A second method proposed is based on the work by Powell et 
al(95) who demonstrated the release of active NGF from a biocompatible ethylene-
vinyl acetate copolymer polymer matrix. When PC 12 cells were exposed to polymer-
conditioned medium, neurite outgrowth was observed, indicating the bioactivity of 
NGF administered in this way. It is possible that such a procedure could be used to 
provide a local source of NGF in the brain for a limited period of time. A third 
method proposed involves coupling NGF to a carrier to enable it to cross the blood 
brain barrier. This has been demonstrated by coupling NGF to an antibody to the 
transferrin receptor. When the conjugate was injected peripherally it successfully 
crossed the blood brain barrier and retained full biological activity of NGF( 96). Cell 
grafting techniques have also been proposed as a method of NGF administration to 
the central nervous system. This would involve transplanting to intracerebral sites, 
cells capable of NGF synthesis. This technique has been demonstrated to be quite 
successful in aninials( 97 ' 98 . Risk of tumour formation using this technique may be 
circumvented by using primary cell lines( 99). Alternatively, it has also been suggested 
that it may be possible to transfer to the brain only the genes necessary to produce 
NGF('°°). 
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An alternative method to using NGF protein for therapeutic treatment of 
Alzheimer's Disease would be to design a molecule which can act as an NGF agonist 
in the brain. There is increasing knowledge of NGF receptors and with the 
knowledge of the crystal structure of NGF it may be possible to identify the regions 
of NGF required for binding and activation of receptors. These smaller peptides 
could then be administered using one of the appropriate techniques outlined above or 
it could be possible to design a smaller organic molecule capable of crossing the 
blood brain barrier, based on the knowledge of the NGF receptor binding site. 
1.2.6 Aim of the Project 
The biological significance of NGF and its potential use for the treatment of 
Alzheimer's Disease is clear. The difficulties of using NGF for treatment have been 
outlined. The knowledge of NGF interaction with each of the receptors could 
provide valuable information for the design of drug treatment for Alzheimer's 
Disease. Knowledge of the amino acid sequence required for binding to p75 and trk 
is limited. Previous work carried Out in this laboratory has provided a good insight 
into the regions of NGF important for binding to p75. It is the aim of this project to 
develop the binding potential of peptide fragments to p75 and to investigate the 
regions of NOF important for trk binding. Competitive binding assays have been 
developed by our collaborators at Parke Davis for each of the NGF receptors. The 
peptide fragments of NGF were to be synthesised by Solid Phase Peptide Synthesis 
techniques. 
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1.3 SOLID PHASE PEPTIDE SYNTHESIS 
1.3.1 Introduction 
During the first half of this century, the synthesis of peptides posed a major 
challenge for organic chemists. The knowledge of biologically active peptides was 
ever increasing. The isolation of these naturally occurring peptides often presents a 
very difficult problem. Therefore, the need for chemical synthesis of these peptides 
and their analogues became increasingly important for pharmacological studies. 
The methods for peptide synthesis were in need of reform. Classical solution 
chemistry could not meet the ever increasing demand for peptide synthesis. Yields 
for the formation of peptide bonds were often quite low resulting in poor overall 
yields for the entire synthesis of a peptide. In the early 1960's a revolution in this 
area of chemistry was brought about by the development by R. B. Merrifield( 101 ) of 
Solid Phase Peptide Synthesis (SPPS). The idea behind this technique is quite 
simple. If an amino acid (A) is anchored to a solid support, it may be allowed to 
react with a large excess of amino acid (B) until the reaction has gone almost to 
100% completion. The excess of B may then be washed away leaving the dipeptide 
formed and attached to the solid support. This procedure may then be repeated for 
each amino acid in the sequence until finally the peptide is complete. The design of 
the solid support is such that it may be easily cleaved to yield a peptide which has 
been synthesised in extremely high yield. Also, there was great potential for 
automation of this system and indeed this has been successfully achieved which 
greatly decreases the length of time involved in the synthesis. 
Initially this technique was met with a lot of sceptism from organic chemists 
who felt instinctively that such high quantitative yields were rare in this area of 
chemistry. However, the Merrifield technique has stood the test of time and it is now 
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used world-wide as a very successful technique for the chemical synthesis of 
peptides. 
1.3.2 The Solid Support 
The original Merrifield resin was a chioromethylated styrene-divinylbenzene 
copolymer (2) Figl.10. Despite much research ink other forms of solid support, the 
original Merrifield resin has stood the test of time and consequently remains the 
preferred solid support resin for most syntheses. Developments have been made, 
however, in the coupling of the peptide chain to the solid support. Many 'linkers' 
have been produced which make cleavage of the peptide from the solid support 
considerably easier. One such linker was developed by Wang( 102) (3). An ester 
linkage may be formed between the Wang linker and the C-terminus of the peptide. 
The p-alkoxy substituent of the benzyl alcohol increases the sensitivity of the ester 
linkage to acid. This enables the solid support to be cleaved by trifluoroacetic acid 
once the synthesis is complete (See Fig. 1.10b). Other solid supports which had been 
used previously including the original Merrifield resin required much more severe 

















Fig. 1. 10 a. The synthesis of the Wang linker. 
b. Cleavage of the Wang linker. 
1.3.3 Protecting Groups 
1.3.3.1 N-a Protecting Groups 
In order to form one particular peptide bond between two amino acids it is 
necessary that the amino group of one amino acid and the carboxy group of the 
second amino acid be protected to prevent all but one possible combination of the 
two amino acids in forming the bond. A number of different a-amino protecting 
groups have been developed. One such group which is widely used is the 
fluorenylmethyloxycarbonyl (Fmoc) group (Fig.1.11). This group is base labile and 
may be easily removed by washing with a solution of 20% piperidine in 
dimethylformamide (DMF). Therefore, if an Fmoc protected amino acid is attached 
to the solid support, the Fmoc group may be easily removed to yield a free amine 
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NIi-R 
group. This in turn may then be treated with the next Fmoc protected amino acid in 
the sequence to form the correct peptide bond. 
The advantages of the Fmoc protecting group are as follows. Firstly, the 
removal of this group in base doesn't affect the peptide linkage to the solid support. 
Secondly, the adduct formed with piperidine (4) is detectable by U.V. at 302nm. 
Therefore the formation of the peptide bond may be monitored for each coupling 
reaction. The amount of Fmoc-piperidine adduct detected correlates directly with the 
amount of Fmoc protected amino acid which reacted with the resin bound free amine 
in forming the peptide bond. 
L.JL..V.L.JJ 	+ 	 Ni I-R 	+ 
( 
a 
co, 	+ 	NH2R 
NC) 
(4) 
Fig.1.11 Cleavage of the Fmoc protecting group by piperidine. 
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1.3.3.2 Side Chain Protecting Groups 
Many of the common amino acids contain side chain functional groups which 
could be sensitive to the reaction conditions applied in SPPS. These side chain 
groups must therefore be protected during the synthesis. Many protecting groups 
have been developed for this purpose, most of which are easily removed in acids 
such as trifluoroacetic acid and therefore may be cleaved at the same time as the 
peptide is being cleaved from the resin. The natural amino acids may be divided in to 
three groups. 
Ala, Asn, Gin, Gly, Ile, Leu, Met, Phe, Pro, Trp, Val 
Each of these are without functional side chains and therefore do not require 
protection, although Asn, Gin and Trp may require protection sometimes. 
Amino acids with OH, COOH, or NH2 side chain functional groups such as 
Thr, Ser, Tyr, Asp, Glu and Lys. 
The OH and COOH groups are protected as the t-butyl ether or t-butyl ester. The 
N112 group of Lys is protected with t-butyloxycarbonyl. Each of these protecting 
groups i..s removable by treatment with acid. 
Arg, His and Cys require special protection. 
Arginine contains an extremely basic guanadino group. Presently the 
preferred choice of protecting group for this is the pen tamethylchromansulphonyl 
group( 103). The most commonly used protecting group for histidine is the 
triphenylmethyl group (Trt). Each of these protecting groups may be cleaved in acid 
also. The protection of cysteine is discussed in the following section. 
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1.3.3.3 Protecting Groups for Cysteine 
Cysteine requires protection during SPPS because of the nucleophilicity of 
the sulphhydryl group. This group could potentially compete with amino groups in 
the acetylation step to form thiol esters. A number of different cysteine protecting 
groups have been reported in the literature. The main ones used in the work carried 
out for this dissertation are listed below. Firstly, there is the triphenylmethyl 
group( 104) (5) Fig. 1.12. This group, is cleaved by acid at the same time as the peptide 
is being cleaved from the resin, to produce thiol peptides. The S-r-butylsulphenyl 
group (6) is a semi-permanent protecting group. It is stable to acidic and basic 
conditions. Deprotection is carried out after the peptide has been cleaved from the 
resin. Reduction of the disulphide bond by phosphines(' 05 ) is the commonly used 
method for deprotection of this group. 
	
L) 	 H 3C-C-CH 3 
0-1--0 1 S S 
I 	 I 
CH2 CH2 
CH OH 
FmocNH'( 	 FmocNH 
0 0 
S-trityl (5) 	 S-t-butyl (6) 
NHCH 3 	 ,NH ... 
H 2 	 H2 	II1Jj 
S 
CH 2 
FmocNH ° (0 	 FmocNH ' j(° 
0 0 
Acm (7) 	 phAcm (8) 
Fig. 1.12 Protecting groups used for cysteine. 
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The acetamidomethyl (Acm) (7) group is also a semipermanent protecting 
group. It is also generally stable to the acidic and basic conditions of SPPS. It may 
be cleaved by a range of electrophilic reagents such as silver triflate( 106), iodine( 107) 
and mercury (II) ions( 108). The advantage of this protecting group over the S-t -
butylsuiphenyl group is its ability to reduce the hydrophobicity of the peptide. By 
increasing the solubility of the crude peptide, this protecting group aids the 
purification procedure. The final cysteine protecting group employed is an Acm 
derivative named phenylacetamidomethyl (phAcm) (8). The additional advantage of 
this protecting group is that it may be cleaved enzymatically under very mild 
conditions 109). 
Cleavage of these protecting groups under the conditions mentioned results in 
the formation of free thiol groups on the cysteines. The exception to this is the 
cleavage of the Acm protecting group with iodine. This reaction yields disulphides 
directly. In all other cases, formation of intramolecular disulphide bonds may be 
achieved by air oxidation( 110) or by reaction in 5-10% dimethylsulphoxide (DMSO) 
in trifluoroacetic acid("). 
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1.3.4 Peptide Bond Formation 
In order to form a peptide bond between two amino acids efficiently, 
chemical activation of the acid function of one is desirable. Activation of the acid 
function makes it more susceptible to nucleophilic attack by the free amino group. 
Two commonly used activation procedures are; 
to form a symmetrical anhydride of the acid function, 
to form an activated ester of the acid function. 
A very good coupling reagent for the formation of symmetrical anhydrides of 
Fmoc protected amino acids is diisopropylcarbodiimide (DIC) (9) Fig.1.13. DIC 
reacts with amino acids to form an 0-acylurea (10). This may then be reacted upon 
by a second equivalent of amino acid forming the symmetrical anhydride (13) with 
release of diisopropylurea. The advantages of this coupling reagent are that it is 
readily available and that the procedure of activation and coupling is relatively fast. 
The advantage over using mixed anhydrides is that the two reactive carbonyl groups 
in symmetrical anhydrides are identical, the same acylated product being obtained 
through attack at either carbonyl centre, which has the disadvantage that half of the 
amino acid remains unreacted and is wasted. 
Formation of an activated ester of the acid function may be carried out by 
reaction with 1 -hydroxybenzotriazole (HOBt)(' 12)  or ethyl- i -hydroxy- 1H- 1,2,3-
triazole-4-carboxylate (HOCt)(' 13)  The adduct formed on reaction of DIC with one 
equivalent of amino acid (10) may be reacted with either of these triazoles to 
generate an activated HOB  (11) or HOCt (12) ester. 
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Fig. 1.14 The synthesis cycle for Fmoc SPPS 
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1.3.5 Problems in Solid Phase Peptide Synthesis 
1.3.5.1 Racemisation 
Of the twenty common amino acids, nineteen have a chiral cx-carbon. Two 
amino acids, isoleucine and threonine, have second chiral centres in their side chains. 
In nature, the a-carbon atoms of amino acids mostly possess the same relative (L) 
configuration. In SPPS, partial conversion to the D configuration of the activated 
amino acid may occur. The mechanism of racemisation is believed to be due to the 
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Fig.1.15 Mechanism of racemisation of activated amino acids in SPPS 
Reprotonation may occur on either face to give the L or D configuration. The 
oxazole, racemised or not, can react with the free amino group on the resin in the 
same way as the original activated amino acid can. This provides a mechanism for 
incorporation of racemic amino acid residues during peptide synthesis. The presence 
of base is a requirement for this mechanism and in normal coupling reactions base 
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would not be present. Therefore racemisation is rarely a problem in this way. 
However, when the first amino acid is being loaded on to the resin, a catalytic 
amount of the base 4-dimethylaminopyridine (DMAP), is usually required. If the 
level of DMAP is too high in the coupling mixture, racemisation of the amino acid 
may occur. 
Histidine creates a problem with racemisation due to the basicity of the 







PG = Protecting Group 
Fig.1.16 Mechanism of histidine racemisation. 
Racemisation may be suppressed through electronic and steric effects of the 
protecting group on N 2. This may be chosen to so as to reduce the basicity of N 1. 
eg. theTrt protecting group. The most effective way of suppressing this racemisation 
is of course to protect N 1. The protecting group tert-butoxymethyl (Bum) is used in 
this way but this material is a lot more expensive than His(trt) and difficult to 
purchase in pure form. 
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1.3.5.2 Deletion Sequences 
Deletion sequences may arise from incomplete coupling reactions. If all the 
amino groups on the resin do not become acylated by the activated amino acid these 
groups will then be available for reaction in the next coupling cycle, having missed 
one amino acid in the sequence. To combat this, the free unacylated amino termini 
may be acetylated by reaction with acetic anhydride. Alternatively deletion peptides 
may arise from the incomplete deprotection of the Fmoc group in one particular 
cycle. This prevents the incoming activated amino acids from coupling with the 
amino terminal, thus giving rise to a deletion sequence being co-synthesised. 
31 
CHAPTER TWO DISCUSSION 
2.1 Introduction 
Much work has been carried Out in recent years on the study of the structure-
function relationships of Nerve Growth Factor. At present there is limited knowledge 
of the areas of NGF required for receptor binding and subsequent biological activity. 
The technique of site directed mutagenesis has been widely used to investigate the 
importance of specific residues for NGF binding and biological responses(' 14 " 8 . 
Chemical modification of reactive amino acid side chains has also been used in these 
investigations. For example, N-bromosuccinimide was used to convert Trp 21 ' 76 ' 99 (all 
evolutionarily conserved residues) to oxindole derivatives(1 I9.120)  This initially 
indicated that these residues were not required for biological activity. However, a 
subsequent study using the same procedure contradicted this( 121 ). Frazier et al 
reported that iodination or nitration of the two tyrosine residues (Tyr 52 .79) indicated 
that these residues are-exposed on the surface of the molecule but that they are not 
required for biological activity( 119). Modification of the lysine residues with 
dimethy1suberimidate 122 or by acetylation or succinylation( 123) was reported to be 
possible without loss of NGF activity. However, modification of the arginine 
residues with cyclohexanedione resulted in inactivation but kinetic analysis suggests 
that the loss in biological activity is due to gross structural change rather than 
modification of specific sites( 123). 
With site directed mutagenesis studies, changes to the NGF primary sequence 
have been made. These mutants were then tested for subsequent changes in binding 
and biological activity of NGF. Ibanez et al have reported that three lysine residues 
(Lys32 ' 34 '95) form a positively charged interface involved in binding to p75(15).  They 
have also reported findings that discontinuous stretches of amino acid residues group 
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together on one side of the NGF dimer to form a continuous surface responsible for 
binding to and activation of trk(' 18)  A series of mouse NGF deletion mutants were 
prepared by Drinkwater et 0117), using in vitro mutagenesis. They tested the 
importance of the N-terminal and C-terminal domains and also the surface exposed 
reverse turn region 59-66, for NGF activity. They found that the C-terminal deleted 
mutant showed no measurable biological activity compared to the full length NGF 
suggesting that this region plays a crucial role in mediating receptor recognition and 
perhaps ligand binding. Mobley et al reported that the amino terminal eight residues 
in murine NOF are susceptible to proteolytic cleavage and were therefore considered 
not to be involved in interactions with the NGF receptors( 124). Full-length and amino-
truncated NGF were considered equal in biological activity based on initial 
experiments performed with mNGF. When recombinant hNGF became available, 
Kahle et al(' 16)  reported that full length recombinant human NGF (rhNGF 1-118) 
was more potent than the amino terminal-truncated rhNGF (rhNGF 10-118) with 
regard to survival of sensory and sympathetic neurons, as well as neurite outgrowth 
from PC12 cells. They found that trk bound full length rhNGF with over 300-fold 
higher affinity than 10-118 rhNGF whereas only a slight difference in affinity of 
binding to p75 was observed. This indicated that for hNGF binding to trk, the N-
terminal region was important. 
More recently the structure-function relationships of NOF have been 
investigated using an alternative and independent technique involving anti-NGF 
monoclonal anti bodies(' 25). This is considered a useful strategy since antigenic sites 
like the receptor binding sites are most likely to be present on the surface of the 
protein. Three well-characterised monoclonal antibodies were used to probe sites on 
the surface of NGF involved in binding to p75 and trk, and their effects on NGF 
binding to the receptors were examined. It was found that one of these antibodies 
(27/21) inhibited biological activity and trk binding and phosphorylation by NGF but 
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did not inhibit p75 binding. This indicated that there are different binding regions for 
each receptor. It was proposed that the antigenic region that may be involved in 
binding to rrk encompasses the N-terminus, the loop region 60-80 and the C-
terminus of NGF. 
In this study the structure activity relationship of Nerve Growth Factor has 
been investigated by the synthesis of peptide fragments of NGF and the subsequent 
testing of the ability of these peptides to inhibit NGF binding to each of the 
receptors. This method has the advantage that the purity of the peptide fragments 
may be assured. Chemical modifications and analogues of the fragments may also 
easily be produced. Previous work carried out on this project in this laboratory, led 
to the identification of a peptide fragment in the C-terminal region which inhibited 
NGF binding to the p75 receptor in micromolar concentrations. This provided the 
starting point of the work carried Out here. 
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2.2 p75 Receptor Binding Assay 
The assay used to test the ability of the NGF peptides to bind to the p75 
receptor was set up by our collaborators at Parke Davis. This assay used full-length 
recombinant human p75, produced from Chinese Hamster Ovary (CHO) cell lines. 
The receptor was biotinylated and then anchored to streptavidin-coated microtitre 
plates. The high affinity of biotin for the protein streptavidin aided this method of 
receptor immobilisation. Incubation for two hours, of 1251-NGF (100pM) with a 
lOp.M solution of peptide in dimethylsuiphoxide (DMSO), was carried out. After a 
careful wash cycle the binding ability of the test peptide was determined by 
comparison of the measured counts per minute for 1251-NGF in the presence and 
absence of the test peptide. If the test peptide competed with 1251-NGF for binding to 
the receptor, the counts per minute would decrease as increased quantities of 





= recombinant p75 
(D = radiolabelled mNGF 
= test peptide 
Fig.2.1 Diagrammatic representation of the p75 assay 
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2.3 Trk Receptor Binding Assay 
The assay used to test the ability of the NGF peptides to bind to the trk 
receptor was set up by our collaborators at Parke Davis. For this assay, recombinant 
human trk receptor produced from Chinese Hamster Ovary (CHO) cells, was used. 
The receptor was attached to microtitre plates using wheatgerm agglutinin (WGA) 
SPA beads. Incubation for one hour at room temperature, of 1251-mNGF (100pM) 
and a 100iM solution of peptide in binding buffer, was carried out. The binding 
buffer consisted of phosphate buffered saline (PBS) with 1mg/mi glucose and 
1mg/mi bovine serum albumin (BSA). 1251-mNGF was obtained from Amersham. As 
with the p75 assay, inhibition of 1251-NGF by the test peptide results in a decrease in 
counts per minute of the receptor-bound 1251-NGF. 
o =test peptide 
0 = radiolabelled mNGF 
= WGA-SPA bead 
11 = recombinant htrk receptor 
Fig.2.2 Diagramatic representation of the trk assay 
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2.4 Synthesis of Analogues of a C-terminal Active Fragment of NGF 
Previous work carried out in this laboratory led to the identification of a C-
terminal fragment of NGF required for binding to the p75 receptor( 126 ' 27). This 
region, which is highly conserved, contains 100-114 NGF. 
R 100 .F.I.R.I.D.T.A.C.V.C.V.L.S.R"4 
It was found that an artificial disulcde bond formed between Cys' 08 and Cys' 1° 
gave a compound which bound with higher affinity than the reduced form( 126" 27). 
The initial work carried out in this study involved the investigation of the importance 
of two of the N-terminal residues of this peptide for binding to the p75 receptor. 
Arg'°° was replaced by lysine and ornithine, Phe'°' was replaced by 
cyclohexylalanine and tyrosine. These substitutions investigated the importance of 
the functional side chains of these residues , for binding to the p75 receptor. 
The synthesis of this sequence proved to be difficult. It was found that using 
standard double couple cycles with symmetrical anhydride and HOBt ester led to a 
drop in the synthesis over the entire sequence to approximately 35% coupling. This 
meant that several deletion sequences would also be present in the crude material and 
purification of the desired peptide would be extremely difficult. It was therefore 
decided that standard coupling procedures were insufficient for this sequence. For 
the synthesis of these analogues, different coupling procedures were investigated in 
an effort to improve the overall yield of purified peptide obtainable from the 
synthesis. 
The first analogue to be synthesised replaced Arg'°° with lysine. This was 
synthesised using standard coupling cycles. A resultant drop in the overall synthesis 
to 35% coupling was observed, as stated above. By examination of the deprotection 
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profile (Fig.2.3), areas of poor coupling could be assessed. This information was 
used in deciding the coupling procedures to be used in subsequent syntheses. It was 
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Fig.2.3 Chain assembly for 100-114 NGF analogues 
From the deprotection profile of the first analogue (Lys 100 SI), areas of poor 
coupling appeared to be Ala 107-Thr' 08 and Asp' 05-Ile 106. Half of the resin was 
removed from the synthesis before the deprotection of Phe'°', but this has been taken 
inç account when calculating the points on the graph for deprotection of Phe'°' and 
Arg 100 . 
The second analogue to be synthesised replaced Argt 0° with ornithine. For 
this synthesis it was decided that triple coupling cycles would be used with extended 
coupling times for Ala' 07-Thr' 08 and Asp' 05-Ile' 06 , as these were the areas of poor 
coupling in the previous synthesis. Extended coupling was also used for the coupling 
of Ile' 02-Phe' 01 . This resulted in a much improved overall coupling efficiency. The 
38 
synthesis ended at approximately 85% coupling compared to 35% coupling observed 
in the previous synthesis. 
The third analogue to be synthesised replaced Phe 10 ' with tyrosine. For this 
synthesis, it was decided to use double couple cycles, as for the first synthesis, but 
with extended coupling times throughout the sequence. Half of the resin was 
removed from the synthesis before deprotection of Ile' 02 and stored for the synthesis 
of the next analogue. Up to this point in the synthesis the coupling had gone as well 
as it did in the previous synthesis where triple coupling cycles had been used. 
However, on coupling of Tyr'°' a 50% drop in coupling was observed (Fig.2.3). 
The synthesis of the fourth analogue with Phe'°' replaced by 
cyclohexylalanine was carried out using the remaining 50% of the resin removed 
from the synthesis of the third analogue. In order to prevent the drop in coupling 
efficiency observed in the previous synthesis for Tyr'°', cyclohexylalanine was 
coupled with triple coupling cycles with extended coupling times. 
Finally the synthesis of the first analogue was repeated (Lys 100 S2), this time 
using double couple cycles with extended coupling times. This synthesis finished at 
65% coupling compared to 35% coupling for the first synthesis. 
Purification of these analogues proved to be quite difficult on account of the 
hydrophobic nature of the sequence. However, it was noted in each case that 
cleavage of the S-t-butyl protecting groups on cysteine and subsequent oxidation of 
the crude peptide, greatly improved the solubility. This indicated that the 
hydrophobic nature of this cysteine protecting group may have been the cause of 
much of the solubility problems incurred. Each of the analogues wo.s tested on the 
p75 assay. A comparison between the analogues and the unchanged sequence 100-
114, was made. The results obtained are summarised in Table 1. 
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p75 Assay 
Amino Acid Sequence 	 % Inhibition 
@ l0jiM 
100-114 NGF 	R.F.I.R.I.D.T.A.C.V.C.V.L.S.R (oxid) 	36 
100-114 Lys 100 K.F.I.R.I.D.T.A.C.V.C.V.L.S.R (oxid) 12 
100-114 0rn 100 O.F.I.R.I.D.T.A.C.V.C.V.L.S.R (oxid) 12 
100-114 Cha'°' R.Cha.I.R.I.D.T.A.C.V.C.V.L.S.R (oxid) 30 
100-114 Tyr'°' R.Y.I.R.I.D.T.A.C.V.C.V.L.S.R (oxid) 10 
Table 1 
From these results it is clear that the substitution of Arg'°° results in a great 
depletion of binding of this sequence. Substitution of Phe 10 ' by tyrosine also 
surprisingly appears to destroy the binding ability of the peptide, whereas the 
substitution by cyclohexylalanine surprisingly does not. This indicates that the 
aromaticity of the side chain group in Phe'°' does not appear to be important for 
stability of binding. It is clear, however, that none of these analogues bind with 
higher affinity than the native sequence of 100-114 NGF. 
2.5 Investigation of a Secondary Binding Site for p75. 
A paper published by Ibanez et a10 15 ) describes a proposal that Lys 32, Lys34 
and Lys95  of NGF form a positively charged interface involved in binding to p75. 
The mutant proteins with these lysine residues replaced by alanine residues showed 
loss of binding to the p75 receptor but retained binding to trk and biological activity. 
This demonstrated a functional dissociation between the two NGF receptors. 
Therefore, it was decided that these lysine residues may form a secondary binding 
site for p75 along with the C-terminal fragment 100-114 NGF previously identified 
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here. It was thought that a peptide combining both of these regions may bind more 
efficiently to the p75 receptor, than the fragment 100-114 NGF, by itself. A peptide 
was therefore designed which linked the C-terminal fragment 100-114 NGF to these 
lysine residues using a straight chain carbon linker, aminoundecanoic acid (aua). The 
flexibility of this linker would hopefully allow the lysine residues to form the 
required positive charged complex for binding to p75 and also allow 100-114 to 
stretch to its receptor binding site. Acm protecting groups were used for the cysteine 
residues as it was expected that this protecting group would improve the solubility of 
the crude peptide. 
The first synthesis of this peptide (compound 8) was carried out using triple 
coupling cycles (one symmetrical anhydride followed by two HOBt activated ester) 
with extended coupling times. The aminoundecanoic acid linkers were coupled 
manually by sonication. The overall synthesis appeared to go quite well ending at 
approximately 60% coupling. Cleavage of the peptide from the resin indicated, 
however, that deletion sequences were also present in the crude material (Fig.2.4a). 
Purification of the required peptide sequence (with Cys still protected) from the 




Fig. 2.4 a. Hplc trace of crude peptide (compound 8). 
b. Purified peptide. 
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A second synthesis of this peptide was carried out (compound 8/2). It was 
decided that a new coupling reagent which was developed in this laboratory( " 3), 
ethyl- 1-hydroxy- 1H-1 ,2,3-triazole-4-carboxylate, would be used as it had been shown 
that this coupling reagent improved the overall efficiency of the synthesis of the 
sequence 100-114 NGF(1 13)•  A new capping solution was also used in this synthesis. 
The new capping solution of 0.5M acetic anhydride, 0.125M disopropylethylamine 
(DIEA), 0.2% HOBt in DMF compared to the old capping solution of 0.5M acetic 
anhydride, 0.5M pyridine in DMF, was believed to be more efficient( 128). The 
deprotection profile for each synthesis indicated that the second synthesis was as 
successful as the first. However, comparison of the hplc traces of the crude peptides 
obtained from each synthesis indicates that a much higher percentage of the required 
peptide compared to deletion sequences was present in the crude material of the 
second synthesis (Fig.2.5). The cleavage conditions for both were the same and the 
cleavage time allowed was three hours. It was clear, therefore, that using the new 
coupling reagent and capping solution had improved the overall efficiency of the 
synthesis. Purification of the crude peptide from the second synthesis proved to be 




Fig.2.5 a. Hplc trace of crude peptide (cysteine protected compound 8/2). 
b. Purified peptide. 
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To form the disulphide between Cys 108  and Cys"°, deprotection of the 
cysteine protecting groups had first to be achieved. Several methods of Acm 
deprotection have been published 10108 . The method which worked best with this 
peptide appeared to be cleavage using silver trifluoromethanesulphonate°°. 
Cleavage of the Acm groups was confirmed by a positive Eliman's test (section 
3.2.6.1). Oxidation was carried out in a solution of 5% DMSO/TFA. The oxidation 
was monitored by analytical hplc (Fig.2.6). In one hour the oxidation had gone 
almost to completion. The reaction was stopped and the peptide was purified by 
preparative hplc. 
--~ k.6~3 9%%B 
t = 0 	 t = 30 minutes 	 t = 1 hour 
Fig.2.6 Oxidation of compound 8/2 in 5% DMSO/TFA 
Both the reduced (with cysteines still protected) and oxidised forms of this 
peptide were tested on the p75 assay. In addition, a peptide containing only the 
lysine extension part of this peptide was also synthesised, i.e. the three lysine 
residues linked to Arg'°° but with Phe'°t to Arg" 4  omitted. This was tested for the 
ability of the lysine residues alone to bind to the p75 receptor. The results obtained 
in the p75 assay are summarised in Table 2. 
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p75 Assay 
Amino Acid Sequence 	 % Inhibition 
@ 10iM 
K32.G.K34.aua.K95.aua.R100.F.I.R.I.D. 
T.A.C(Acm).V.C(Acm).V.L.S.R 114 	 49 




100-114 NGF R.F.I.R.I.D.T.A.C.V.C.V.L.S.R (oxid) 	 19 
Table 2 
From these results it was immediately apparent that there was a problem with 
the p75 assay as the percentage inhibition value for the sequence 100-114 NGF was 
only about half that of the usual value obtained (36% inhibition @ lOp.M). However, 
it was also clear that the lysine chain attached to the peptide 100-114 greatly 
increased the inhibition of NGF (60%, 82% inhibition compared with 19% 
inhibition) with the oxidised from of this linker peptide showing greater inhibition 
than the cysteine protected form. Interestingly, the lysine residues alone, without the 
sequence 100-114 attached, did not show much inhibition. The following photograph 
illustrates how these lysine residues and the C-terminal fragment 100-112 (113-120 
not determined in the crystal structure) relate to the 3-D structure of the NGF protein 
itself. This photograph shows the configuration of the murine protein as found by X-
ray crystallography. The plate was prepared from the Brookhaven Protein Databank 
model of murine NGF and manipulated using the SYBIL programme on an Evans 
and Sutherland workstation. It is interesting to note the close proximity of the three 
lysine residues to Arg'°° and Arg 103 . It seems likely that these residues form part of a 
positively charged unit involved in binding to the acidic p75 receptor. 
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Plate 1 
The protein structure of mNGF showing in red, the basic residues Lys 95 ' 32 '34 and 
the region 100-112 NGF. (Residues 113-120 not resolved in the crystal 
structure). 
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2.6.4 Initial Trk Assay Results of the NGF Peptides. 












Amino Acid Sequence 
59-67 (h) R.D.P.N.P.V.D.S.G 
46-54 (h) N.S.V.F.K.Q.Y.F.F 
34-42 (m) K.E.V.T.V.L.A.E.V 
50-60 (h) K.Q.Y.F.F.E.T.K.C.R.D 
81-107 (h) T.T.T.H.T.F.V.K.A.L.T.M.D.G.K.Q.A.A. 
W.R.F.I.R.I.D.T.A 
25-40 (h) 	K.T.T.A.T.D.I.K.G.K.E.V.M.V.L.G 
1-8.aua.100-114 (h) S.S.S.H.P.I.F.H.aua.R.F.I.R.I.D.T.A. 
C.V.C.V.L.S.R (oxid) 
(h) = human sequence, (m) = mouse sequence. 
Table 3 
The four peptides, which were purified and tested to confirm the epitope scan 
results (59-67, 46-54, 34-42 and 50-60), appeared to contradict the results. However, 
it should be noted that for the epitope scan, peptides of mouse sequence were used. 
This may be a contributing factor to the low inhibition values observed for these 
human sequence peptides. Alternatively, it may be that none of these peptides 
contains the entire sequence required for binding and a longer sequence from this 
region is required. The peptides containing the two loop regions (81-107 and 25-40) 
also showed very little inhibition in the trk assay. However, a very interesting result 
was obtained for the peptide involving the N-terminal region of NGF. This peptide 
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showed 83.4% inhibition of NGF binding, at a concentration of 100tM. Initially it 
was thought that this result indicated good activity due to the N-terminal eight 
residues. At the same time, our collaborators at Parke Davis synthesised a number of 
peptides from this N-terminal region. These peptides and their results on the trk 
assay are summarised in Table 4. 



















Ac = acetylated peptide 
Table 4 
It was clear from these results that the N-terminal region of NGF did not appear to 
have great inhibitory effects on NGF binding to the trk receptor. This led us to 
investigate the ability of the peptide 100-114 to inhibit NGF binding to the trk 
receptor. 
2.7 Investigation of the C-terminal Fragment 100-114 For Binding to Trk. 
The sequence 100-114 NGF was synthesised (compound 16) using double 
couple HOCt coupling cycles. The cysteine residues were incorporated as the S-t-
butylsulphenyl derivatives. Bromotrimethylsilane (TMSBr) was used in the cleavage 
solution when the peptide was being cleaved from the resin. Thus the cysteine 
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protecting groups were cleaved at the same time as the peptide was being cleaved 
from the resin (see section 2.8.2 pg. 58). The hplc trace of the crude peptide 
indicated a very good synthesis (Fig.2.9a). The peptide was oxidised in 5% 
DMSO/TFA and purification by preparative hplc led to the desired compound in 
very pure form (Fig.2.9b). This peptide was the tested on then trk assay. The results 
obtained are summarised in Table 5. 
a. 	 b. 
Fig.2.9 a. Hplc trace of crude 100-114 NGF. 
b. Purified peptide after oxidation in 5% DMSO/TFA. 
Trk Assay 
Amino Acid Sequence 	 % Inhibition @ Xj.iM 
100-114 NGF R.F.I.R.I.D.T.A.C.V.C.V.L.S.R 	 100 @ 200p.M 
(oxidised) 	 100 @ 100p.M 
92@50p.M 
85 @ 10.tM 
Table S 
These results indicate that the peptide 100-114 NOF has an IC 50 value, i.e. 
the concentration required for 50% inhibition of NGF binding, of less than 10iM. 
Thus it has been found that this C-terminal fragment appears to be important for 
NGF binding to both p75 and trk receptors. The next question concerned how this 
53 
peptide inhibited NGF binding. It was not known if the peptide bound to the 
receptors and thus inhibited NGF binding or if the peptide simply bound to NGF and 
somehow interfered with the receptor binding region of NGF. It was important to 
attempt to resolve this question in order to be able to predict whether or not this 
peptide could act as a potential agonist for NGF. 
2.8 Investigation of the Method of Inhibition of Trk Binding by Test Peptides 
In order to study the interaction of 100-114 NGF with the trk receptor it was 
decided that a tyrosine residue which could be radioiodinated should be attached to 
the N-terminus of 100-114 NGF. With the radiolabelled peptide, it should be 
possible to test whether the peptide bound to NGF or to the rrk receptor. 
2.8.1 Synthesis of Tyr99.100-114 NGF 
The peptide Tyr99 .100-114 NGF was synthesised manually using the 
apparatus shown in appendix 1. The cysteine residues were incorporated as the S-t-
butylsulphenyl derivatives. Cleavage of the peptide from the resin in 
90%TFA/2%phenol/4%EDT/4%H20 was monitored by analytical hplc. Cleavage of 
up to six hours did not appear to improve the hplc profile of the crude peptide 
(Fig.2. 10). The crude material was found to be very hydrophobic. It was thought that 
this was probably due to the cysteine 
protecting groups. An attempt to cleave 
the S-t-butyl groups did not appear to 
improve the hplc profile either 
(Fig.2.11). It was clear that this peptide 
Fig.2.10 Hplc trace of crude peptide. 	would not be easily purified and 
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therefore it was decided that the peptide 
should be synthesised again with 
incorporation of Acm protecting groups 
for the cysteine residues. It was 
predicted that this would improve the 
solubility of the crude peptide and thus 
hopefully aid the purification of the 
peptide. A second synthesis was carried 
Fig.2.11 Crude peptide after 
cleavage of S-t-butyl groups 
out, this time on the peptide synthesiser, using double couple HOCt coupling cycles. 
After coupling of Arg 100, a small sample of resin was removed from the synthesis 
and the peptide was cleaved using the same conditions as before. An analytical hplc 
recorded on the crude material thus obtained showed a greatly improved profile than 
that of the crude material from the first synthesis (Fig.2.12a). Coupling of the 
tyrosine residue to the remaining resin-peptide was carried out by overnight 
sonication with the HOBt ester of Fmoc-tyrosine. The peptide was cleaved from the 
resin and an analytical hplc was recorded of the crude peptide (shown in Fig.2. 12b). 
It was clear from comparison of Fig.2.12a and b that the coupling of the tyrosine 
residue to the peptide had in some way affected the cleavage of the peptide from the 
resin. Once again, purification would be difficult. It was decided that another 
synthesis would be carried out, this time using the compound p-hydroxyphenylacetic 
acid in replace of the tyrosine residue. 
a. '- 
/V7  B 
	 b. 
Fig.2.12 a. Hplc trace of crude 100-114 NGF before coupling Tyr 99 . 
b. Crude peptide after coupling Tyr 99 
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2.8.2 Synthesis of p-Hydroxyphenylacetic acid-100-114 NGF 
The synthesis of this peptide was first carried out using double couple HOCt 
coupling cycles and incorporating the cysteine residues as the Acm derivatives. Once 
again, a small amount of resin was removed from the synthesis after coupling of 
Arg'°°. The peptide was cleaved from the resin and the hplc profile of the crude 
material obtained may be seen in Fig.2.13a. Once again the success of the synthesis 
of the sequence as far as Arg'°° was evident. To the remaining resin-peptide 
p-t-butoxyphenylacetic acid (BUPA) was coupled by forming the symmetrical 
anhydride. The hplc profile of the crude material obtained on cleavage of this 
peptide from the resin may be seen in Fig.2.13b. By comparison of the hplc profiles 
in Fig.2.13a and b, it appeared that the coupling of p-hydroxyphenylacetic acid to the 
N-terminus of 100-114 was a success. I 
a. 
Fig. 2.13 a. Hplc trace of crude 100-114 NGF before coupling BUPA. 
b. Crude 100-1 14NGF after coupling and deprotection of BUPA. 
This peptide was purified by preparative hplc. However, an attempt to cleave 
the Acm protecting groups from the cysteine residues using silvertrifluoromethane 
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suiphonate resulted .in very low yields (approximately 4%). It was apparent that in 
order to obtain enough material for radiolabelling and subsequent rrk receptor 
interaction studies, an alternative method would have to be applied. By comparing 
the results of the various attempts to synthesise either this peptide or the N-terminal 
tyrosine peptide, it was decided that using p-hydroxyphenylacetic acid in place of 
tyrosine appeared to have improved the possibility of obtaining a good overall yield 
of the required peptide. However, the Acm protecting groups used in the synthesis of 
the p-hydroxyphenylacetic acid peptide considerably reduced the overall yields of 
the oxidised peptide to be obtained as cleavage of these protecting groups proved to 
be difficult. It was therefore decided that another synthesis of this peptide should be 
carried out, once again using p-hydroxyphenylacetic acid instead of tyrosine for the 
N-terminal residue but with incorporation of the cysteine residues as the S-r-
butylsulphenyl derivatives. It was hoped that this cysteine protecting group would be 
more easily cleaved than the Acm protecting group. The synthesis of this peptide 
(compound 15) was carried Out using double couple HOCt coupling cycles. The 








Arg Sr leu V& Cy5 Vol CY5 Al. Thr Mp lie Arg lie Phe Arg 
Residue 
Fig.2.14 Chain assembly for compound 15. 
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After coupling of Arg'°°, a small amount of resin-peptide was removed from the 
synthesis and cleaved in 90%TFA/2%pheflo/4%EDT/4%H20. The hplc trace of the 
crude material obtained is shown in Fig.2.15. It was immediately apparent that the 
hplc profile did not reflect the efficient coupling achieved during the synthesis. It 
was considered that the nature of the bulky hydrophobic cysteine protecting groups 
contributed to the lack of resolution observed by analytical hplc. Alternative 
cleavage conditions were considered. It was decided that it may be advantageous to 
deprotect the cysteine residues at the same time as the peptide was being cleaved 
from the resin. This procedure would decrease the hydrophobicity of the crude 
peptide and thus aid purification. It was thought that the absence of the bulky S-t-
butyl groups in the crude peptide may improve the resolution of the crude peptide on 
hplc. 
Fig. 2.15 Hplc trace of crude 100-114 NGF before coupling BUPA. 
Deprotection of S-t-butyl groups at the same time as cleavage of the peptide 
from the resin has been reported to be achieved by using bromotrimethylsilane 
(TMSBr) with TFA( 130 . A small amount of resin-peptide was cleaved using the 
reported cleavage solution of 7 .5m1TFA/500t1EDT/ 1 OOj.tlm-cresol/l. I 7ml 
thioanisole/1.3mITMSBr. The reaction was carried out at 0°C under N 2. The hplc 
profile of the crude material thus obtained is shown in Fig.2. 1 6a. A positive Ellman's 
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test indicated that the cysteine protecting groups had been cleaved. The comparison 
of Fig.2.15 and Fig.2.16a indicated therefore that the presence of the bulky, 
hydrophobic S-r-butyl protecting groups in the crude peptide contributed mainly to 
the lack of resolution observed in Fig.2.15. To the remaining peptide-resin, BUPA 
was coupled by symmetrical anhydride activation. Cleavage of the resin-peptide 
using TMSBr in TFA was carried Out. The analytical hplc profile of the crude 
peptide thus obtained may be seen in Fig.2.16b. There was clearly a marked 
improvement in the resolution of this material compared to that obtained by the usual 
TFA cleavage procedure used up to this point. Oxidation of the peptide in 5% 
DMSO/TFA and subsequent purification by preparative hplc yielded the required 
peptide (compound 15). The hplc trace of the final purified product is shown in 
Fig.2.16c. This peptide was then sent to Parke Davis where the radiolabelling and 
subsequent trk receptor interactions were examined. 
a. C. 
58%B 
Fig.2.16 a. Crude 100-114 from cleavage in TFA with TMSBr. 
Crude peptide after coupling BUPA, cleaved in TMSBr with TFA 
Purified peptide (compound 15). 
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2.8.3 Cleavage of Tyr99.100-114 with Bromotrimethylsilane in TFA. 
The use of bromotrimethylsilane in the cleavage solution for compound 15 
prompted an investigation into the use of this cleavage solution for the peptide 
previously synthesised with tyrosine coupled to the N-terminus of 100-114. As 
explained above, purification of this peptide was not pursued due to the poor 
resolution observed in the hplc trace for the crude material obtained from the TFA 
cleavage solution. However, it was unclear whether the lack of resolution was due to 
the S-t-butyl cysteine protecting groups or if the tyrosine residue in some way 
affected the cleavage of the peptide from the resin. In order to resolve this question, 
peptide-resin from the first synthesis of Tyr 99 .100-114 NGF (with S-t-butyl 
protecting groups on the cysteine residues) was cleaved at 0°C under N 2 using the 
reported TMSBr cleavage solution of 7.5m1 TFA/500tl EDT/100.tl m-cresol/1.17m1 
thioanisole/1.3m1TMSBr. The hplc of the crude peptide obtained is shown in 
Fig.2.17a. A positive Ellmans test indicated that deprotection of the cysteine 
residues had occurred. By comparing this hplc trace with Fig.2. 11, it is clear that the 
lack of resolution seen in Fig.2. 11 is due to the cysteine protecting groups and not 
the tyrosine residue. This peptide (compound 11) was purified (Fig.2.17b) and 
analysis by mass spectrometry and amino acid analysis verified it to be the title 
compound. 
tv 
B 	 b. NjB 
Fig.2.17 a. Hplc trace of crude Tyr99 .100-114 cleaved using TEA with TMSBr. 
b. Purified peptide. 
2.8.4 Results of p-Hydroxyphenylacetic acid-100-114 in the Trk Receptor Assay. 
Before the peptide was radioiodinated it was tested in the rrk assay for its 
ability to inhibit NGF binding. It was necessary to establish that the p-
hydroxyphenylacetic acid group did not interfere with 100-114 inhibition of NGF 
binding. It was found that this peptide showed 100% inhibition of NGF binding at 
100.tM concentration indicating that the inhibition of NGF binding by 100-114 was 
not decreased by the p-hydroxyphenylacetic acid residue. Subsequent radiolabelling 
was carried out and it was confirmed that the peptide 100-114 did not bind to NGF 
in the trk assay( 131 ). Inhibition of NGF was achieved by the binding of the peptide to 
the trk receptor confirming that this peptide represents at least part of the binding site 
of NGF to the trk receptor. This indicates that 100-114 NGF may act as a potential 
agonist for NGF binding to the receptor. 
2.9 Further NGF Receptor Binding Site Studies. 
2.9.1 General 
Previous work was carried out in this laboratory involving the investigation 
of a secondary binding site region in NGF for the p75 receptor( 127). The region 50-70 
was linked to 95-120 by five glycine residues and an attempt to selectively form each 
of the disulphides Cys 58-Cys 108  and Cys68-Cys" 0  was made. This region 50-70 was 
chosen in particular because of the possibility of forming two of the three disulphide 
bonds which are present in NGF. However, attempts to form both disulphides were 
not successful. It was decided that the idea of synthesising a peptide containing the 
native disulphides should be reconsidered. It was thought that the function of the 
disulphides could possibly be to bring closer together the residues needed for 
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interaction with the receptors. Considering 100-114 NGF was found to be required 
for binding to both the p75 and the trk receptors, the discontinuous peptide linking 
together residues 50 to 70 and 100 to 114, was suggested. The carbon chain linker 
aminoundecanoic acid was to be used to join the two peptide fragments. The 
advantage of this linker over using a glycine chain linker was that it was hoped that 
aminoundecanoic acid would form a less rigid system and would allow the peptide 
fragments to come together to form the required disulphide bonds. It was decided 
that both the mouse and human sequences of this peptide would be synthesised as 
this would include four changes in the sequence 50 to 70 NGF (K 50 to R, D60 to A, 
61 to S, D65 to E). The peptides were to be tested on both assays. 
2.9.2 Assembly of 50-70.aua.100-114 hNGF (compound 19). 
The peptide was assembled on Wang resin using double couple HOCt cycles. 
Fmoc-aminoundecanoic acid was coupled manually as the HOBt ester, by overnight 
sonication. The cysteine protecting groups were chosen so as to allow selective 
formation of each of the disulphides. Cys 58" 08 were incorporated as the S-t-
butylsuiphenyl derivatives. Cys68.1 10 were incorporated as the 
phenylacetamidomethyl derivatives. The deprotection profile indicated that the 
synthesis went well, ending at approximately 60% coupling. 
2.9.3 Deprotection and Cleavage from the Resin. 
Cleavage of the peptide from the resin was carried Out at 0C under N 2 in 
7.5mlTFA/500.tlEDT/1 OOpim-cresol/ 1.1 7mlthioanisole/ 1. 3m1TMS Br. The hplc 
profile of the crude material obtained after three and five hours shown in 
Fig.2.18a. Cleavage for longer than 5 hours was not considered necessary. Cleavage 
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under these conditions would also have resulted in the deprotection of the S-t-butyl 
protecting groups on Cys 58 ' 108 . Purification of the reduced peptide by preparative 








Fig. 2.18 a. Hplc trace of crude compound 19 cleaved in TFA with TMSBr. 
b. Purified reduced peptide. 
2.9.4 Analysis of the Reduced Peptide 
The reduced form of compound 19 was analysed by TOF mass spectroscopy. 
A single peak at 4660.6 was observed (Fig.2. 19). This molecular weight agreed with 
that expected for the peptide with Cys 58•'°8 deprotected and Cys68'110 still protected 
by phenylacetamidomethyl groups. A positive ElIman's test also indicated the 
presence of free thiol groups which was in agreement with this analysis. 
Fig.2.19 TOF mass spectrum of reduced compound 19. 
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2.9.5 Oxidation of Cys58-Cys' °8  with DMSO. 
Formation of the first disulphide bond was carried out by dissolving the 
reduced material in 5% DMSOTTFA. After one hour oxidation, the retention time of 
the peptide on analytical hplc had changed from 21 minutes for the reduced peptide 
to 19 minutes for the oxidised peptide (Fig.2.20a). Subsequent purification by 
preparative hplc was carried out. The hplc trace of the final purified material 
obtained is shown in Fig.2.20b. Analysis of this material proved it not to be the 
required peptide with just one disulphide formed. During the DMSO oxidation of 
Cys58 to Cys 108  the phAcm protecting groups on Cys 68 and Cyst 1 ° were unexpectedly 
cleaved also. This was evident from the mass spectroscopy results (Fig.2.21). A 
negative Eliman's test indicated 	that 	all 	four cysteine residues were oxidised. 
Selective oxidation of each of the disulphides was therefore not achieved and it 





t=O 	S 	 t=lhour 
Fig. 2.20 a. Oxidation of Cys 58-Cys'° 8 in 5% DMSO/TFA. 
b. Purified peptide. 
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Fig.2.21 TOF mass spectrum of compound 19 oxidised in 5% DMSOITFA 
Cleavage of the phAcm protecting groups in this way was unexpected. 
However, Akaji et al have reported( 132) that Acm protecting groups on cysteine may 
be cleaved to form cystine directly with diphenylsulphoxide, in the presence of 
methyltrichiorosilane. It is possible, therefore, that following the cleavage of this 
peptide in bromotrimethylsilane, a certain amount of silyl salts were still present 
with the peptide during the DMSO oxidation. Perhaps there was enough 
contamination for the catalysis of the cleavage of the phAcm groups, to take place. 
As the peptide had been purified by preparative hplc after cleavage from the resin, it 
was not to be expected that any silyl salts would still be present. 
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2.9.6 Glutathione Oxidation of Cys 58-Cys108 . 
The conditions of the oxidation of Cys 58-Cys 108 in DMSO/TFA proved to be 
too harsh for the stability of the phAcm protecting groups on CyS68.110.  Therefore, it 
was decided that more gentle oxidation conditions such as oxidation with glutathione 
should be applied. Glutathione is present in vivo in the reduced, GSH, and oxidised, 
GSSG, forms. It is thought to act as an electron acceptor-donor couple in disulphide 
exchange reactions. The formation of a disulphide using the reduced and oxidised 
forms of glutathione is represented in Fig.2.22. 
E[ 
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Fig.2.22 Formation of a disulphide with glutathione. 
This is an equilibrium process which results in the formation of the most 
dynamically stable disulphide. Following the procedure described by Ramage a 
al(133 ) for the formation of a disulphide in the peptide endothelin using glutathione, 
the oxidation of Cys 58-Cys 108  was carried out by dissolving the reduced peptide 
(10mg, 1x10 5M) in buffer at pH 8.0 containing 0.1 Immole oxidised and 1.1mmole 
reduced glutathione. The reaction was stirred overnight at 4 0C and the oxidation was 
monitored by analytical hplc (Fig.2.23) which indicated that the reaction appeared to 
go to completion in 24 hours. Purification by preparative hplc gave the pure, 
disulphide linked Cys 58-Cys 108  peptide (2mg). A negative Eliman's test verified that 
the disulphide had been formed. Analysis by TOF mass spectroscopy verified that 
the phAcm protecting groups on Cys 68 ' 0  were unaffected by the oxidation. The 
glutathione oxidation was carried out on a remaining 45mg of reduced peptide. This 





t=O 	 t=2hours 	 t=24,72hours 
Fig.2.23 Glutathione oxidation of Cys 58-Cys' 08  monitored by analytical hplc. 
2.9.7 Attempted Formation of Cys 68-Cy&'° Disulphide. 
The protecting group used for Cys 68 " 	 phenylacetamidomethyl, has been 
reported to be cleaved enzymatically by penicillin acylase( 109). This procedure was 
tried on a small scale. However, on addition of the resin bound enzyme to the 
peptide dissolved in buffer, the peptide was adsorbed by the resin and therefore it 
was not possible to follow the cleavage of the protecting groups by analytical hplc. It 
was not possible to ascertain if deprotection had taken place. Cleavage of the phAcm 
groups had earlier been unexpectedly achieved by DMSO/TFA. Therefore it was 
decided that this procedure could be tried again. The cleavage and oxidation in 5% 
DMSOITFA was followed by analytical hplc. Fig.2.24 shows the change in hplc 
profile observed over a two hour period. 
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t=O 	 t=2hours 
Fig.2.24 Attempted cleavage of phAcm groups and formation of Cys 68-Cys 11 ° 
disulphide with 5% DMSO/TFA. 
It was clear that a reaction had occurred but the product gave a rather broad 
peak compared to the pure starting material. The nature of the broad peak indicated 
that dimerisation had possibly occurred. Given the small amount of material that was 
left to work with at this stage it was decided that the peptide with one disulphide 
formed should be sent to Parke Davis for testing and no further attempt at forming 
the second disulphide was made. 
2.9.8 Synthesis of 50-70.aua.100-114 mNGF (compound 21). 
The synthesis and purification of this peptide was carried out exactly as for 
the human sequence peptide (compound 19). As with compound 19, the DMSO 
oxidation of Cys58 to Cys'°8  resulted in cleavage of the phAcm protecting groups 
from Cys68 . 110  and both disulphides were formed simultaneously. Purification was 
achieved by preparative hplc. 
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2.9.9 Results of Human and Mouse 50-70.aua.100-114 NGF in the p75 Assay. 
The following results were obtained when these peptides were tested in the 
p75  assay: 
Amino Acid Sequence 
50-70.aua.100-114 hNGF (oxid) 
50-70.aua.100-114 mNGF (oxid) 
50-70.aua.100-114 hNGF 
p75 assay 
% Inhibition ® 10pM 
10 
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(Cys58 ' 108 oxidised, Cys68 ' 110  phAcm protected) 	 10 




The results in Table 6 show that a possible secondary binding site may be 
present in the mouse sequence 50-70 NGF. This peptide showed 72% inhibition of 
NGF at lOj.tM compared to 34% inhibition for 100-114 NGF. The human sequence 
did not indicate any such inhibition. However, it is not clear whether this may be due 
to incorrect disulphide formation for this peptide. Perhaps the correct disulphides 
were formed when the DMSO oxidation was carried out on the mouse sequence 
peptide. The peptide with just one disulphide formed shows a decrease in binding 
compared to 100-114, also. It may be that formation of the second correct disulphide 
would recover the binding observed for the mouse sequence. The following 
photograph illustrates how these two binding regions relate to the 3-D structure of 
the NGF protein. It is possible that the function of the disulphides is to bring closer 
together the residues required for binding to the receptor. 
Plate 2 
The protein mNGF showing the region 100-112 (red) and 50-70 (green) 
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2.10 Investigation of the Importance of the N-terminal Region of NGF for p75 
Receptor Interaction. 
It was mentioned earlier that the N-terminal region of NGF was investigated 
for interaction with the trk receptor. The peptide 1-8.aua.100-114 NGF was 
synthesised and subsequent testing indicated that the N-terminal region of NGF did 
not interact with the trk receptor. The same peptide was also tested in the p75 assay 
to see if enhancement of binding by the N--terminal region of NGF could be achieved 
for this receptor. The following results were obtained: 
Amino Acid Sequence 
1-8.aua. 100-114 hNGF (oxidised) 
1-8.aua. 100-114 mNGF (oxidised) 
100-114 (oxidised) 
p75 Assay 





From the results in Table 7 it was clear that the N-terminal eight residues in 
hNGF appeared to enhance the binding of 100-114 to the p75 receptor. The mouse 
sequence of this peptide was also synthesised and tested. There are two changes in 
the N-terminus of NGF between the human (h) and mouse (m) sequences, Ser 3 (h) to 
Thr (m) and lie6 (h) to Val (m). Interestingly, the result obtained for the mouse 
sequence indicated that the N-terminal region is not important for NOF binding to 
the p75 receptor, as reported by Mobley( 124 ). 
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2.11 Further Investigation of 100-114 NGF Binding to Trk. 
Previous studies had identified 100-114 NGF as the minimum sequence from 
the C-terminal region of NGF, required for binding to the p75 receptor(' 26,127).  It was 
found here that this peptide bound to the trk receptor also but it was not known if 
this sequence represented the optimum binding sequence from the C-terminal region. 
It was therefore decided that extended sequences from the C-terminal region would 
be synthesised in an effort to enhance binding to the trk receptor. In addition, 
investigations of the functional importance of the artificial disulphide Cys'° 8-Cys 110 
for trk binding, was studied. The reduced form of 100-114 NGF was synthesised, as 
well as a peptide which replaced Cys-Val-Cys with a proposed n-turn mimic cis-1-
amino-4-carboxy-cyclopentane 134 (compound 20). There is a precedent for making 
this substitution; work carried out in this laboratory showed that replacing Cys-Val-
Cys in a peptide sequence from gpl20, GC1( 135), by this proposed n-turn mimic, 
resulted in a peptide which retained the full biological activity of GC1( 136). This was 
an interesting observation as Cys-Val-Cys has been shown to fulfil the requirements 
of an ideal y-turn conforrnation( 137 . Making this substitution in 100-114, it was 
hoped would give some indication of the necessity of the disulphide for interaction 
of 100-114, with the receptors. The peptides synthesised are listed in Table 7. 
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Amino Acid Sequence 
	 Cmpd. no 
	
100-114 NGF 	 R.F.I.R.I.D.T.A.C.V.C.V.L.S.R (reduced) 
	
16 
111-120 mNGF 	 V.L.S.R.K.A.T.R.R.G 
	
17 
95-120 mNGF 	 K95.Q.A.A.W.R.F.I.R.I.D.T.A.C.V.C.V. 
L.S.R.K.A.T.R.R.G 120 	(reduced) 
	
18 






(Turn = proposed n-turn mimic) 
Table 7 
Thus, extension of the fragment 100-114 NGF as far as residue 95 on the N-
terminus and 120 on the C-terminus was achieved with the peptide 95-120 NGF. 
This peptide was first synthesised in the reduced form. An attempt at air oxidation of 
Cys 108-Cys 110  in ammonium acetate (pH 8.0) resulted in dimerisation of the peptide 
instead of the expected intramolecular disulphide formation. It is believed that NGF 
may bind to the receptors as a dimeric form so it was decided that this dimer should 
be tested for enhanced binding, in both receptor assays. 
The C-terminal residues 112-120 NGF are poorly defined in the crystal 
structure of NGF. This is possibly due to the flexibility and solvent accessibility of 
this region. Drinkwater et al(117) reported that the seven carboxy-terminal amino 
acids in mNGF, 112-118, are required for biological activity. It was therefore 
decided that a peptide containing the C-terminal residues should be synthesised and 
tested in the rrk assay. This peptide 111-120 was chosen so as to avoid the cysteine 
residues and related purification problems, and yet to include the seven carboxy-
terminal residues. It was thought that perhaps the flexibility of this region may 
indicate a receptor binding region. In addition, the peptide 50-70.aua.100-114 
synthesised initially for testing on the p75 assay was also tested on the trk assay. 
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The peptides were tested on both receptor assays. The results obtained are 
summarised in Table 8 below. 
Amino Acid Sequence 











95- 120 mNGF (reduced) 	 24 
95-120 mNGF (dimer through cysteine residues) 31 
100-107.Turn.111-114 	 100 
50-70.aua.100-114 hNGF 	 100 
(Turn = proposed 13-turn mimic) 
Table 8 
77 
(IC 50 = 0.32tM) 
-17 
10 
As may be seen from the results obtained on the trk assay, extending the 
sequence 100-114 NGF appeared to result in a depletion of receptor binding. 
Interestingly, the reduced form of 100-114 did not show any inhibition of NGF 
binding to trk. This is consistent with the result that replacement of Cys-Val-Cys 
with the proposed 13-turn mimic retained the inhibition previously observed for 100-
114 in the oxidised form. This indicates that the cysteine residues are not important 
for binding of 100-114 NGF to trk but instead, the structural constraint implied by 
the disulphide is what is important. Replacement of this structural constraint by the 
proposed 13-turn mimic, retained the binding ability of the peptide. On the contrary, 
replacement of the disulphide appears to have completely destroyed the ability of the 
74 
peptide to bind to the p75 receptor. This indicates that there is a possible interaction 
between the cysteine residues and the p75 receptor. On removal of these residues, 
binding to the receptor is destroyed. 
While the peptide 95-120 did not appear to inhibit NGF binding to the trk 
receptor, a very interesting result was obtained for the dimer of this peptide, in the 
p75 assay. This dimer peptide gave an IC 50 value of 0.32.tM in the p75 assay. This 
result represents the best result obtained to date for interaction of an NGF fragment 
with the p75 receptor. It is possible that the high density of positively charged 
residues required for binding to the p75 receptor may never be obtained from a 
monomer fragment of NGF. If the dimer succeeds in presenting a higher density of 
charged residues it perhaps better mimics the binding of NGF which possibly binds 
in the dimeric form. 
2.12 Summary and Conclusions. 
The initial aim of this study was to identify regions in the NGF protein which 
appeared to be involved in receptor-interaction. Interaction with both NGF receptors, 
p75 and trk was studied. Previous work carried Out in this laboratory had led to the 
isolation of a C-terminal fragment of NGF required for binding to the p75 
receptor( 126" 27). This fragment was 100-114 NGF. 
R'°°.F.I.R.I.D.T.A.C.V.C.V.L.S.R" 4 
Substitutions of various residues in the sequence in previous work and in this study 
did not lead to a reduction in the IC 50 value for this sequence. 
A secondary binding site in NGF for the p75 receptor was investigated. The 
lysine residues Lys 95, Lys32 and Lys 34 appeared to enhance binding to the p75 
receptor when combined with the fragment 100-114 NGF. Computer analysis clearly 
shows the close proximity of these lysine residues with Arg'°° and Arg' 03 in the 
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native protein. Formation of the disulphide between Cys 108 and Cys"° could possibly 
also bring Arg 114 in close proximity of this region. Together these basic residues may 
form a complex which interacts with the highly acidic p75 receptor. The lysine 
residues alone did not appear to have any binding interaction with the receptor 
indicating that the combination of both regions is required for higher affinity binding 
to p75. 
Replacing the disulphide in 100-114 NGF by a proposed n-turn mimic, 
completely destroyed the binding of this peptide to the p75 receptor indicating that 
the cysteine residues may also play an active part by interacting directly with the 
cysteine-rich p75 receptor. Alternatively, the change in conformation implied by this 
13-turn mimic may have sufficiently altered the spatial orientation of the amino acids 
contained in the sequence which make direct contact with the receptor. 
Other regions of NGF investigated for secondary binding sites to p75 
included the N-terminal region and the region 50-70 NGF. The N-terminus of hNGF 
appeared to give a 2-fold increase in the binding affinity to p75. This region was not 
clearly defined in the crystal structure, possibly due to its flexibility. This may 
therefore indicate a region flexible enough to interact with the receptor. On the 
contrary, the region 50-70 NGF is well characterised in the crystal structure. This 
region is involved in two of the three disulphides formed in native NOF. Following 
the hypothesis that the function of the disulphides is to bring closer together the 
residues required for direct receptor interaction, the peptide 50-70.aua. 100- 114 was 
synthesised and an attempt to form two of the native disulphides was made. It was 
not clear which way the disulphides formed in the final product but certainly for the 
mouse sequence peptide a two-fold increase in percentage inhibition of NGF to the 
p75 receptor was noted in comparison to that obtained for the peptide 100-114 NOF. 
This increase was not found for the human sequence peptide indicating that incorrect 
disulphides possibly had formed in this peptide, or that the amino acid changes 
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between the human and mouse sequences for the 50-70 region are very significant. 
Further investigation would be required in order to clarify this point. 
Interestingly, it was found that the lowest IC 50 value obtained for peptide 
interaction with the p75 receptor was with a dimeric form of the C-terminal fragment 
95-120 NGF. This peptide was dimerised through the two cysteine residues Cys 108 ' 110 
and gave an IC50 value of 0.32tM which represents a tenfold increase compared to 
that obtained for the monomer of 95-120 NGF. Possibly the increase in charge 
density obtained with the dimer is the reason for greater binding to the acidic p75 
receptor. It is thought that NGF binds as a dimer to the receptor so it is possible that 
a dimeric form of the active site better mimics the binding of NGF to the receptor 
and thereby shows greater inhibition of NGF binding. 
The investigation of NGF interaction with the trk receptor highlighted the 
importance of the C-terminal fragment 100-114 for trk receptor binding also. This 
surprising result prompted the question of how this peptide succeeded in inhibiting 
NGF binding to both receptors. Attachment of a radiolabelled residue to the N-
terminus of the 100-114 NGF sequence allowed receptor-interaction of the peptide to 
be studied. It was thought possible that the peptide could in some way interact with 
NOF and alter the conformation of the binding site and thereby inhibit binding of 
NGF. However, it was found that the radiolabelled peptide did not bind to NOF in 
the trk assay. Binding to the trk receptor was observed. This indicates that the 
sequence 100-114 NGF represents at least part of the binding site of NGF for each 
receptor and therefore may possibly be developed as an agonist for NGF. 
Although the sequence 100-114 NGF was found to bind to both NGF 
receptors, a difference in the functional importance of structure of the sequence for 
binding to both receptors was observed. The proposed 13-turn mimic substituted for 
Cys.Val.Cys, completely destroyed binding of the sequence to p75 but not to trk. 
This implied that the cysteine residues may be involved in direct interaction with the 
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cysteine-rich p75 receptor. Substitution of these cysteine residues may therefore 
severely inhibit the direct interaction of the peptide with the p75 receptor. This 
substitution did not affect interaction with the trk receptor indicating that the relative 
orientation of the residues when the 1,3 disulphide is replaced by the proposed 3-turn 
mimic, is sufficiently similar to be able to uphold the required conformation for 
binding to the rrk receptor. This hypothesis is consistent with the finding that the 
reduced form of 100-114 NGF (which obviously lacks the structure implied by the 
disulphide) does not bind to the rrk receptor but appears to bind with similar affinity 
as the oxidised form to the p75 receptor. In addition, the dimeric form of 95-120 
shows a ten-fold increase in binding to the p75 receptor but a decrease in binding 
compared to the oxidised 100-114 NGF peptide binding to the trk receptor, is 
observed. This dimeric form of 95-120 would not have the same structural 
constraints as the oxidised form of 100-114, further implicating the importance of 
relative spatial orientation of the residues for trk receptor interaction. 
Attempts to further enhance the binding of 100-114 NGF to trk by extending 
the sequence as far as Lys 95 on the N-terminus and Gly 120  on the C-terminus did not 
produce any significant results. Once again, this could possibly be due to the linear 
form of these peptides. Perhaps even further enhancement of binding may be 
achieved by imposing a structural constraint in the sequence 95-120 such as 
formation of the disulphide Cys' 08-Cys"° or by replacement of the disulphide with 
the above mentioned n-turn mimic. 
Preliminary results suggest that combination of the human sequence 50-70 
NGF with 100-114 shows better inhibition of binding to the trk receptor than to the 
p75 receptor. Unfortunately, mouse sequence 50-70.aua.100-114 was not tested in 
the trk assay so a direct comparison of the relative importance of the mouse and 
human sequence of 50-70 NOF for each receptor cannot be made. 
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The results presented here indicate for the first time a region of NGF which is 
involved in binding to both p75 and trk receptors for NGF. A possible secondary 
binding site for p75 has also been identified. Different structural constraints implied 
in the C-terminal active fragment have highlighted separate requirements for binding 
of this region to each receptor. The translation of these results into the construction 
of compounds with agonistic activity for the neurotrophin NGF is a possibility. It is 
hoped that such compounds could then be developed for pharmacological interest in 
the treatment of neurological disease. A complete list of results obtained for all the 
peptides synthesised in this study and in previous studies(' 26 .' 27), is given in 
Appendix 2. 
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CHAPTER THREE: EXPERIMENTAL 
3.1 NOTES 
All Fmoc-amino acids were purchased from either Novabiochem, Bachem or 
Raylo with exception to Fmoc-Cys(phAcm) which was synthesised in this laboratory 
by Angus Brown( 138) and Kirstie Urquhart( 134) and Fmoc-aminoundecanoic acid 
which was synthesised by Jenny Henry( 139). The 3-turn mimic Fmoc-1-amino-4-
carboxy-cyclopentane described for compound (20) was synthesised by Kirstie 
Urquhart( 134). Fmoc-t-butoxyphenylacetic acid used in compound (15) was 
synthesised by David Pallin( 140). The peptides were synthesised on an ABI 430A 
peptide synthesiser. Peptide synthesis grade dimethylformamide (DMF) and 1,4-
dioxan were obtained from Rathburn Chemicals. Peptide synthesis grade 
trifluoroacetic acid (TFA) was obtained from Applied Biosystems. Ultraviolet 
spectra were recorded on a Varian Cary 210 double beam spectrophotometer. All 
other instrumentation used is described in the relevant sections in the text. 
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3.2 SOLID PHASE PEPTIDE SYNTHESIS 
3.2.1 Coupling of the First Amino Acid to the p-Alkoxy Benzyl Alcohol (Wang) 
Resin. 
Fmoc-L-amino acid (1.6mmoles) was dissolved in DMF (5mls). To this 
solution diisopropylcarbodiimide (0.8 mmoles) was added and the solution was 
allowed to stir for 15 minutes. The symmetrical anhydride of the Fmoc amino acid 
thus formed was then added to 0.5g of Wang resin (0.8 mmole/g), pre-swollen in 
DMF (5m1). 4-dimethylaminopyridine (DMAP, 10mg) was also added and the 
mixture was sonicated for 2 hours. The resin was then filtered and washed well with 
DMF, followed by washing with 1,4-dioxan. 
3.2.2 Determination of the Loading of Amino Acid on the Wang Resin. 
Approximately 10mg of resin loaded with Fmoc-amino acid was washed with 
diethyl ether. After filtration the resin was allowed to air-dry under suction for 
approximately 30 minutes. To an accurately weighed sample (approximately 3mg) of 
resin-amino acid, a solution of 20% piperidinefDMF (lOml) was added. This was 
sonicated for 30 minutes. The U.V. absorbance of the piperidine-Fmoc adduct 
formed was detected at 302nm. The loading of the resin was calculated by a 
computer programme using the Beer-Lambert law after calibration with known 
quantities of Fmoc-Gly-OH. The procedure was carried out in duplicate and an 
average value of the product resin functionality was used to determine the weight of 
resin-amino acid required to carry out the synthesis on a 0.25mmole scale. 
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3.2.3 Peptide Assembly on Wang Resin. 
The weight of resin-amino acid required to carry out the synthesis on a 
0.25mmole scale was determined as outlined in section 3.2.2. The correct weight of 
resin loaded with the first amino acid was then placed in a clean reaction vessel and 
the synthesis was carried out using a 430A Applied Biosystems peptide synthesiser. 
The Fmoc-L-amino acids (0.5mmole) were weighed into cartridges and loaded into 
the machine. The amino acids were activated for coupling using one or more of the 
three methods listed below. 
3.2.3.1 Formation of Symmetrical Anhydride 
Fmoc-amino acid (immole) was dissolved in DMF (4m1) and a solution of 
0.25M DIC in 1,4-dioxan (2m1) was added. A further 2m1 of 1,4-dioxan was added 
and the solution was allowed to stand for 10 minutes in the activator vessel before 
being added to the reaction vessel. The standard coupling time allowed was 30 
minutes. If extended coupling was used the coupling time allowed was one hour. 
3.2.3.2 Formation of HOBt Ester 
Fmoc-amino acid (0.5mmole) was dissolved in a solution of 0.25M HOBt in 
DMF (2m1). This was diluted with DMF (2m1) and transferred to the activator 
vessel. A solution of 0.25M DIC in 1,4-dioxan (2m1) was added along with a further 
2ml of 1,4-dioxan. This was allowed to stand for 15 minutes before being transferred 
to the reaction vessel. The standard coupling time allowed was 30 minutes. If 
extended coupling was used the coupling time allowed was 90 minutes. 
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3.2.3.3 Formation of HOCt Ester. 
Two methods were used for the formation of the HOCt ester. The first 
method involved weighing HOCt (0.5mmole) into cartridges similar to those used 
for the amino acids. These were then loaded into the machine in the same way as the 
amino acid cartridges. DMF (2m1) was used to dissolve the HOCt. The Fmoc-amino 
acid (0.5mmole) was dissolved in DMF (2m1) also and both were transferred to the 
activator vessel. A solution of 0.25M DIC in 1,4-dioxan (2m1) was added along with 
a further 2ml of 1,4-dioxan. The solution was allowed to stand for 15 minutes before 
being transferred to the reaction vessel. 
The second method of forming the HOCt ester was exactly the same as for 
the HOBt ester. The coupling times allowed were also the same as for the HOBt 
ester. 
3.2.3.4 Capping the Resin 
After coupling the Fmoc-amino acid the N-a protected resin was washed four 
times with 50:50 DMF/1,4-dioxan (lOmls). Two different capping solutions have 
been used: 
Capping solution A: 0.5M pyridine, 0.5M acetic anhydride in DMF; 
Capping solution B: 0.5M acetic anhydride, 0. 125M DIEA and 0.2% HOBt in DMF; 
In either case the solution (lOmi) was transferred to the reaction vessel and the resin 
was capped for 10 minutes. Finally the resin was washed five times with 50:50 
DMF/1,4-dioxan (lOmis). For most of the peptides described herein capping solution 
B was used unless otherwise stated. 
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3.2.3.5 Deprotection of Fmoc from the Coupled Amino Acid. 
A solution of 20% piperidine/DMF (lOmis) was transferred to the reaction 
vessel and deprotection of Fmoc took place over 3 minutes. The resin was washed 
with 50:50 DMF/1,4-dioxan and a second batch of deprotection solution was added 
to the reaction vessel. Deprotection for 1 minute was allowed. A sample of each 
deprotection mixture was analysed by an ABI 758A absorbance detector, with on-
line integration via a spectra-physics SP4400 ChromJet integrator/printer. U.V. 
detection was carried out at 302nm. By comparing the integration peaks for the 
Fmoc deprotection of each coupled amino acid, the percentage of amino acid 
coupled could be determined. Finally the resin was washed five times with 50:50 
DMF/1,4-dioxan. 
3.2.4 Acidolytic Cleavage of the Peptide from the Resin 
After peptide assembly the resin-peptide was washed with diethyl ether 
(50m1) or DCM (50m1) and filtered. The resin-peptide was allowed to air dry under 
suction for at least one hour before cleavage. The standard cleavage solutions used 
were as follows: 
Cleavage solution A: 
0.75g phenol, 0.25m1 EDT, 0.5ml thioanisole, 0.5m1 H20, 8ml TFA 
Cleavage solution B: 
400.tl EDT, 400tl H20, 200mg phenol, 9.Oml TFA 
Cleavage solution C (carried out under N 2 at OoC): 
7.5m1 TFA, 500tl EDT, 100tl m-cresol, 1.17m1 thioanisole, 1.3ml TMSBr 
The cleavage mixture used was made up and then added to the dry peptide-
resin and stirred using a magnetic stirrer. The cleavage solution used and the 
cleavage time allowed were determined by carrying out small scale trial cleavages. 
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Analysis was carried Out by analytical hplc of aliquots of the reaction mixture at 
regular intervals. The conditions used for each individual peptide is described in the 
text. After the allowed cleavage time the resin was filtered and the cleavage solution 
was evaporated under high vacuum to yield an oily mixture. The peptide was then 
triturated with diethyl ether. The diethyl ether was filtered off and the peptide was 
dissolved in an acetic acid and water solution and freeze dried overnight. 
3.2.5 Purification of Peptides by Reversed Phase Hplc 
The crude peptide obtained was first analysed by analytical hplc. The hplc 
machines used were: 
AB  model 151A separation system; 
Gilson 305 controller pump with ABI 785A programmable absorbance 
detector. 
The solvent system used to elute the peptides was: 
Solvent A: H 20/0.l% TFA; 
Solvent B: CH 3 CN/0.1% TFA. 
The columns used are described below, 
Aguapore RP300 reversed phase silica (300 A pore size. 7pm spherical silica 
column 1: 220 x 4.6mm C 18 
column 2: 100 x 4.6mm C 18 
column 3: 200 x 4.6mm C 8 
Vydac reversed phase silica column (300 A pore size. 5.tm spherical silica 
column 4: Vydac 218TP54 C 18 
column 5: Vydac 208TP54 C 8 
For each peptide the analytical gradient used was 5% solvent B to 95% 
solvent B over 30 minutes at a flow rate of lml/minute. The eluent was monitored at 
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214nm. Unless otherwise stated in the text the samples were injected into a 2.Oml 
loop. 
The peptides were purified by preparative hplc. One of the following 
columns were used: 
column 6: Aquapore RP300 C 18 110 x 10mm 
column 7: Aquapore RP300 C 18 200 x 10mm 
column 8: Vydac 218TP1022 200 x 25mm 
column 9: Aquapore RP300 C 8 250 x 10mm 
column 10: Aquapore RP300 C 8 110 x 10mm 
The particular column used depended on the quantity of peptide to be purified and 
on the peptide length. The solvent gradient was chosen to give best resolution of the 
required peptide from the deletion sequences also present in the crude material. The 
conditions used for the purification of each peptide are stated in the text. The 
fractions collected from each prep run were then combined and freeze-dried. The 
purity of the peptide was checked by recording an analytical hplc under the same 
conditions as used for the crude peptide. 
3.2.6 Analysis of Purified Peptides 
The peptide obtained by the procedure outlined in section 3.2.5 was analysed 
by amino acid analysis, fast atom bombardment (FAB) and time of flight (TOF) 
mass spectroscopy. For amino acid analysis, the peptide was hydrolysed in HC1 for 
24 hours at 110°C. Analysis was carried out on an LKB 4151 amino acid analyser. 
FAB mass spectra were recorded on a Kratos MS50TC machine. TOF mass spectra 
were recorded on a Perspective Biosystems LaserTec Benchtop II laser desorption 
(337nm, 400.tJ N 2 laser, 2800V) time of flight system from Vestec mass 
spectrometry products. 
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3.2.6.1 ElIman Assay for Thiols 
The Eliman assay detects the presence of free thiols in a protein or peptide. 
Approximately 0.1mg of peptide is dissolved in a solution (2ml) of 6M GdmCl with 
0.1M phosphate buffer (pH 7.3) and 1mM EDTA. A solution (100tl) of 3niM 
dithionitrobenzoic acid (in 0.IM phosphate buffer, pH 7.3) is added. A positive test 
indicating the presence of free thiols is indicated by the presence of a yellow colour 
compared to a standard solution. A negative test gives a clear solution. 
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3.3 EXPERIMENTAL 
Synthesis of 100-114 hNGF with Orn replacing Arg'°° 	 (2) 
O'°°F.I.R.I.D.T.A.C.V.C.V.L.S.R' 14 
Fmoc-Arg-resin (570mg, 0.25mmole/g) prepared as outlined in section 3.2.1 
was placed in a reaction vessel and the peptide was assembled using triple coupling 
cycles (symmetrical anhydride coupling followed by double HOBt coupling) for 
each amino acid. Standard coupling times were used except for the HOBt coupling 
of Ala-Thr, Asp-Ile and Ile-Phe, where extended coupling times were used. Capping 
solution A was used (section 3.2.3.4). The cysteine residues were incorporated as the 
S-t-butylsulphenyl derivatives. 
The peptide was cleaved from the resin for 3 hours using cleavage solution A 
(section 3.2.4). The cysteine protecting groups were cleaved by dissolving the 
peptide (50mg) in a solution of 95% TFE/H 20 (10mls). Tributylphosphine (10O.11) 
was added and the solution was allowed to stir for 3 hours. The TFE solution was 
then evaporated in vacuo. The peptide was triturated with diethyl ether and dried in 
vacuo. An analytical hplc was recorded (column 3, lOOj.tl loop) and this showed a 
large peak at 44% solvent B. Oxidation of this material was carried Out by dissolving 
the peptide (30mg) in a solution of 10% DMSOITFA (Sml) and stirring for 1.5 
hours. The solution was then evaporated in vacuo. The peptide was triturated with 
diethyl ether and dried in vacuo (yield 13mg). Purification was carried out by 
preparative hplc (column 9) using a gradient of 10-25% solvent B over 10 minutes 
followed by 25-45% solvent B over 20 minutes. After lyophilisation, 5mg of the title 
compound was obtained; amino acid analysis: Asp 1 1.17, Thr 1 l.35, Ser 1 1.14, 
Ala 1 l.17, Va12 1.73, Ile2 l.89, Leu 1 1.31, Phe 1 0.86, Orn 1 0.85, Ar922.04, Cys2n.d.; m/z 
(FAB) 1710 [Mt], HRMS C 74 H 124 N22S 2020 requires 1707.90378 found 1707.90377; 
hplc (column 1, 5.Oml loop) R=17.5minutes. 
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Synthesis of 100-114 hNGF with Tvr replacing Phe'°' 	 (3) 
R.Y.I.R.I.D.T.A.C.V.C.V.L.S.R 
Fmoc-Arg-resin (570mg, 0.25mmole) prepared for compound (2) was placed 
in a reaction vessel and the synthesis was carried out using double couple cycles 
(symmetrical anhydride followed by HOBt) with extended coupling times. Capping 
solution A was used (section 3.2.3.4). After coupling 1le 102 half of the resin was 
removed and stored for the synthesis of compound (4). The cysteine residues were 
incorporated as S-t-butylsulphenyl derivatives. The Fmoc deprotection peak for 
Tyr' 01 (section 3.2.3.5) showed that there was a drop of approximately 50% in the 
coupling of this residue. 
The peptide was cleaved from the resin for 3 hours using cleavage solution A 
(section 3.2.4). The cysteine protecting groups were cleaved using the same 
procedure as for compound (2). The crude dithiol peptide (25mg) was dissolved in 
10% DMSO/TFA (5m1) and oxidation was allowed to proceed for one hour. The 
DMSO/TFA solution was reduced to approximately 0.5m1 by evaporating in vacuo. 
The peptide was triturated with diethyl ether. An analytical hplc was recorded 
(column 1, 2.Oml loop). This showed the presence of two main peaks at 49% and 
45% solvent B. Purification of the peptide by preparative hplc was carried Out 
(column 7) using a gradient of 10-40% solvent B over 30 minutes. After 
lyophilisation 1.0mg of the title compound was obtained. The procedure was 
repeated on a further 47.3mg of crude dithiol peptide to yield 2.5mg of the title 
compound; amino acid analysis: Asp 1 l.05, Thr 1 l.09, Ser 1 l.15, Ala 1 l.18, Val22.04, 
1le22.02, Leu 1 1.18, Tyr 1 0.81, Ar932.96, Cys2n.d.; m/z (FAB) 1767.3 [M], HRMS 
C75H 128N24021 S 2 requires 1767.93621 found 1767.92163; hplc (column 4, 2.Oml 
loop) R=14minutes. 
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Synthesis of 100-114 hNGF with Cyclohexvlalanine replacing Phe 10 ' 	 (4) 
R.Cha.1.R.I.D.T.A.C.V.C.V.L. S.R 	Cha = Cyclohexylalanine 
The peptide-resin which was removed from the reaction vessel after coupling 
of Tie' 02 in compound (3) was used for this synthesis. To this peptide-resin Ch&°' 
and Arg 100 were coupled with triple extended coupling cycles (symmetrical 
anhydride followed by double HOBt) to prevent the 50% drop in coupling observed 
with Tyr'°' in compound (3). 
The peptide-resin was cleaved and the cysteine protecting groups were 
removed, as for compound (3). An analytical hplc was recorded (column 1, 2.Oml 
loop). This showed the presence of one main peak at 50% solvent B. The crude 
dithiol peptide (35mg) was dissolved in 10% DMSO/TFA (5ml) and oxidation was 
allowed to proceed for 1.5 hours. The solution was then reduced to approximately 
0.5m1 by evaporation in vacuo. The peptide was triturated with diethyl ether and air-
dried (yield 22mg). An analytical hplc recorded under the same conditions as for the 
reduced peptide showed that the main peak eluted at 49% solvent B. The peptide was 
purified by preparative hplc (column 7) using a gradient of 10-40% B over 30 
minutes. After lyophilisation, 4.5mg of the title compound was obtained; amino acid 
analysis: Asp 1 1.17, Thr 1 1.12, Ser 1 1.10, Ala 1 1.16, Val22.08, 11e22. 16, Leu 1 1.22, 
Ar93 3.16, Cys2n.d., Cha 1 n.d.; m/z (FAB) 1756.9 [M], HRMS C75H 134 N24020S 2 
requires 1755.97252 found 1755.97243; hplc (column 4, 5.Oml loop) R=18minutes. 
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Synthesis of 100-114 hNGF with Lys replacing Arg'°° 	 (5) 
K.F.I.R.I.D.T.A.C.V.C.V.L.S.R 
Fmoc-Arg-resin (340mg, 0. 15mmole/g) prepared for compound (2) was 
placed in a reaction vessel and the peptide was assembled using double couple cycles 
(symmetrical anhydride followed by HOBt) with extended coupling times. Capping 
solution A was used (section 3.2.3.4). The cysteine residues were incorporated as the 
S-r-butylsulphenyl derivatives. 
The peptide was cleaved from the resin for 3 hours using a cleavage solution 
of 62.5 %TFA/7.5%phenol/20%H 20/1 0%anisole. The cysteine protecting groups 
were cleaved from the crude peptide as for compound (2). The cleavage was 
monitored by analytical hplc (column 1, 2.Oml loop) and after 3 hours the main 
peptide peak had moved from 60% solvent B to 51% solvent B indicating the 
cleavage of the hydrophobic protecting groups had gone to completion. Oxidation of 
the crude dithiol peptide (56.3mg) was carried Out in 10% DMSO/TFA (lOmi) for 
one hour. The oxidation was monitored by analytical hplc using the same conditions 
as above. The oxidised product eluted at 50% solvent B. The DMSOTTFA solution 
was reduced to approximately 0.5m1 by evaporation in vacuo and a solution of 20% 
AcOH was added. The insoluble particles were filtered off and purification by 
preparative hplc was carried Out (column 7) using a gradient of 10-40% solvent B 
over 30 minutes. After lyophilisation, 7.5mg of the title compound was obtained; 
amino acid analysis: Asp 1 l.11, Thr 1 1.04, Ser 1 1.09, Ala 1 1.14, Va122.06, Ile2 l.94, 
Leu 1 l.14, Phe 1 0.99, Lys 1 l.01, Arg2 l.81, Cys2n.d.; m/z (FAB) 1721.7 [Mt], HRMS 
C75H 128N22020S 2 requires 1721.91942 found 1721.91936; hplc (column 4, 2.Oml 
loop) R=15minutes. 
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Synthesis of Lys.Gly.Lys.aua.Lys.aua. 100-114 hNGF 	 (8) 
K32.G.K34.aua.K95 .aua.R'°°.F.I.R.I.D.T.A.C(Acm).V.C(Acm).V.L.S .R' 14 
Fmoc-Arg-resin (595mg, 0.25mmole) prepared as outlined in section 3.2.1 
was placed in a reaction vessel and the peptide was assembled as far as Arg 100 using 
triple couple cycles (one symmetrical anhydride followed by two HOBt cycles). 
Extended coupling times were used. Capping solution A was used (section 3.2.3.4). 
The cysteine residues were incorporated as the Acm derivatives. After coupling 
Arg'°° the percentage loading of the resin was checked manually using the procedure 
outlined in section 3.2.2. The resin loading at this point in the synthesis was found to 
be 0.162 mmole/g. Fmoc-amirtoundecanoic acid (348mg, 0.825mmole) was 
dissolved in DMF (20mls). DIC (0.825mmole) and HOBt (0.825mmole) were added. 
To the HOBt ester of Fmoc-aminoundecanoic acid thus formed, the peptide-resin 
(1.0194, 0.165mmole) was added. The resin was sonicated overnight. This resulted 
in 68% coupling of Fmoc-aminoundecanoic acid. Using the same procedure, a 
second overnight coupling was carried Out. This increased the coupling percentage to 
91%. The resin was capped for 15 minutes. The resin was washed with DMF before 
deprotection of Fmoc with 20% piperidine/DMF (lOmis) was carried out. This was 
followed by a further washing of the resin-peptide with DMF. Fmoc-Lys (936mg, 
2mmole) was dissolved in lOmIs DM,F and DIC (immole) was added. The 
symmetrical anhydride was allowed to form by stirring for 15 minutes before adding 
the peptide-resin. After 2 hours the percentage coupling was found to be 86%. A 
second symmetrical anhydride coupling for 1 'hour increased the percentage coupling 
to 98%. The resin was then capped and Frnoc deprotected. Fmoc-aminoundecanoic 
acid was coupled to Lys 95 using the same procedure as for coupling to Arg'°°. After 
two overnight HOBt couplings the percentage coupling was found to be 84%. A 
third overnight coupling did not improve on this. The resin was therefore capped and 
Fmoc deprotected. The coupling of Fmoc-Lys 34 to aminoundecanoic acid was 
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carried out using double symmetrical anhydride coupling. The resin was then capped 
before being returned to the reaction vessel of the peptide synthesiser. After Fmoc 
deprotection, G1y 33 was coupled by symmetrical anhydride activation of Fmoc-Gly 
(2mmole). Extended coupling time was used. Finally Lys 32 was coupled using 
double couple symmetrical anhydride activation with extended coupling times. 
Cleavage of the peptide from the resin was carried out for 3 hours using 
cleavage solution B (section 3.2.4). Purification of the cysteine protected peptide 
(80mg) was carried out by preparative hplc (column 8) using a gradient of 10-35% B 
over 8 minutes followed by 35-65% over 25 minutes. After lyophilisation, 4.0mg of 
the title compound was obtained; amino acid analysis: Asp 1 l.15, Thr 1 l.06, Ser 1 l.16, 
G1y 1 1.05, Ala 1 1.07, Va122.13, 11e2 1.9, Leu 1 1.1, Phe 1 0.97, Lys3 2.77, Ar93 2.97, 
Cys2n.d.; m/z (FAB) 2700.4 [Mt], HRMS C 123H221 N35028 S 2 requires 2702.64974 
found 2702.64977; hplc (column 1, 5.Oml loop) R L=18minutes. 
Synthesis of oxidised form of (8) 
	
(8/2) 
K32 .G.K34 .aua.K95 .aua.R '°°.F.I.R.I.D.T.A.C.V.C.V.L.S.R" 4 
Fmoc-Arg-resin (520mg, 0.25nimole) prepared as outlined in section 3.2.1 
was placed in a reaction vessel and the peptide was assembled as far as Arg'°° using 
double couple HOCt cycles. The cysteine residues were incorporated as the Acm 
derivatives. Capping solution B was used (section 3.2.3.4). After coupling Arg'°°, 
50mg of peptide-resin were removed and cleaved for three hours using cleavage 
solution B (section 3.2.4). An analytical hplc (column 1, 2.Oml loop) of the crude 
peptide was recorded. This showed a large single peak at 46%B indicating the 
success of the synthesis thus far. The couplings of the aminoundecanoic acid and the 
lysine residues were carried out exactly as for (8). After replacing the peptide-resin 
in the reaction vessel of the peptide synthesiser, G1y 33 was coupled as in (8). Finally 
Lys32 was coupled using double couple HOCt coupling cycles. 
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The resin-peptide was cleaved for 3 hours using cleavage solution B 
(section3.2.4). An analytical hplc (column 4, 2.Oml loop) of the crude peptide 
showed one main peak at 52% B. Purification of the cysteine protected peptide 
(290mg) was carried out as for (8). After lyophilisation 81.3mg was obtained. To 
deprotect the cysteine residues, the peptide (30mg, 1.11 x  10 moles) was cooled in 
ice and silver trifluoromethane suiphonate (57mg, 2.22x 10 moles, 20 equivalents) 
was added. This was then dissolved in TFA (4m1). The reaction was stirred in the 
dark at 0°C for 1.5 hours. The TFA was evaporated off in vacuo and the peptide was 
precipitated by addition of diethyl ether. The silver salt of the peptide thus formed 
was dissolved in 50% acetic acid (5mls) and dithiothreitol (17 1mg, 1.1 1x10 3 moles, 
100 equivalents) was added. The reaction was stirred at room temperature, in the 
dark, overnight. The yellow precipitate thus formed was separated. by centrifugation 
(4,500 rpm for 30 minutes). The supernatant liquid was purified by preparative hplc 
(column 7) using a gradient of 10-35% over 10 minutes followed by 35-50% over 15 
minutes. After lyophilisation, 13.8mg of reduced peptide was obtained. A positive 
Ellman's test carried Out (section 3.2.6.1) indicated the presence of free thiol groups. 
Oxidation of the peptide (12.7mg) was carried in 5% DMSOiTFA (lOmIs). The 
oxidation was monitored by analytical hplc (column 1, 2.Oml loop). After one hour 
the peak at 55% B corresponding to the reduced peptide was replaced by an earlier 
eluting peak at 52% B. The DMSOITFA solution was reduced to approximately 2ml 
by evaporation in vacuo. This was diluted to a volume of 9mls using 40% 
solventB/solventA (section 3.2.5) and purification was carried Out by preparative 
hplc (column 7) using a gradient of 10-40%B over 30minutes. After lyophilisation, 
6.0mg of the title compound was obtained; amino acid analysis: Asp 1 l.06, Thr 1 l.00, 
Ser 1 0.98, G1y 1 1.00, Ala 1 1.06, Va1 22. 17, Ile2 l .91, Leu 1 1.02, Phe 1 1.04, Lys33. 17, 
Ar93 3.08, Cys2n.d.; m/z (TOF) 2556.32 [Mt], HRMS C 117H2 N33026S 2 requires 
2559.57923, found 2559.5678 1; hplc (column 4, 5.Oml loop) R=16minutes. 
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Synthesis of Lys.Glv.Lvs.aua.Lvs.aua.Arg 
	
(9) 
K32 G.K34 .aua.Lys95.aua.Arg 100 
Fmoc-Arg-resin (516mg, 0.25mmole) was prepared as explained in section 
3.2.1. The peptide was assembled manually, up to the coupling of G1y 33 , using the 
same procedure as for the corresponding part of peptide (8/2). The coupling of 
Fmoc-aminoundecanoic acid was carried out by forming the HOBt ester (immole) 
and sonicating overnight. A second overnight coupling was not required. The resin 
peptide was then placed in a reaction vessel and the remaining residues were coupled 
on the machine. G1y 33 was coupled by symmetrical anhydride activation (2mmole) 
with extended coupling time. Lys 32 was coupled using double couple cycles 
(symmetrical anhydride and HOBt activation) with extended coupling times. 
The peptide-resin was cleaved for 2.5 hours using cleavage solution B 
(section 3.2.4). An analytical hplc (column 1, 5.Oml loop) showed one main peak 
eluting at 53%B. The peptide (80mg) was purified by preparative hplc (column 8) 
using a gradient of 10-90% B over 30 minutes. After lyophilisation 10mg of the title 
compound was obtained; amino acid analysis: G1y 1 1.12, Lys32.9, Arg 1 0,96; m/z 
(FAB) 983.3 [Mt] C48H95 N 1308 requires 983.38; hplc (column 2, 5.Oml loop) 
R= 1 6minutes. 




Fmoc-Ala-resin (463mg, 0.25mmole) prepared as outlined in section 3.2.1 
was placed in a reaction vessel and the peptide was assembled using double couple 
HOCt cycles with standard coupling times. 
The peptide was cleaved from the resin (70mg) for 3 hours using cleavage 
solution B (section 3.2.4)(crude yield 23mg). The peptide was purified by 
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preparative hplc (column 6) using a gradient of 10-60% solvent B over 25 minutes. 
After lyophilisation, 1 1m of the title compound was obtained; amino acid analysis: 
Asp2 1.82, Thr65.85, G1u 1 1.25, G1y 1 1.06, A1a44.36, Val 1 l.06, Met 1 l.04, 11e22.10, 
Leu 1 1.05, Phe22.09, His 1 1.02, Lys22.12, Ar922.11, Trp 1 n.d.; m/z (FAB) 3084.3 
[Mt], HRMS C 13811219N39039 S 1 requires 3080.62129; found 3080.61849; hplc 
(column 4, 5.Oml loop) R19.5minutes. 




This peptide was synthesised manually using the apparatus shown in 
Appendix 1. Fmoc-Arg-resin (550mg, 0.25mmole) prepared as outlined in 
section3.2.4 was placed in the bubbler. The synthesis was carried Out by the 
following order of steps. 
1.DMFwash, 10  1 minute 
20% piperidine/DMF, 1 x 5 minute 
DMF wash, 10 x 1 minute 
Kaiser test 
Couple Fmoc-amino acid 
DMF wash, 10 x 1 minute 
Kaiser test 
If Kaiser test negative return to step 2 and continue. If Kaiser test positive return 
to step 5. 
Each amino acid was coupled (step 5) for one hour as symmetrical anhydride 
(2mmole) followed by two hours HOBt (Immole) coupling. The manual monitoring 
of coupling efficiency was carried out by a Kaiser test. The procedure for the Kaiser 
test is as follows: 
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Kaiser Test: 
A small sample of washed peptide-resin was removed from the bubbler, 
placed in a vial and the following solutions were added. 
0.28M ninhydrin in ethanol (75jil), 
2 x 10 M potassium cyanide / pyridine (100.tl), 
76% w/w phenol I ethanol (75tl). 
Each of these solutions were obtained from ABI (peptide synthesis reagents). 
The vial was heated at 100 0C for 7 minutes. A positive test indicating the presence of 
free amine groups was shown by a blue colour. 
The cysteine residues were incorporated as the S-t-butylsulphenyl 
derivatives. The peptide was cleaved from the resin for three hours using cleavage 
solution C (section 3.2.4). Purification of the crude dithiol peptide (30mg) was 
carried out by preparative hplc (column 8) using a gradient of 10-60% over 28 
minutes. After lyophilisation, 5.0mg of the title compound was obtained; amino acid 
analysis: Asp 1 1.27, Thr 1 1.27, Ser i l.06, Ala 1 1.18, Va122.00, 11e22.08, Leu 1 1.13, 
Tyr 1 l.01, Ar93 3.18, Cys2n.d.; m/z (TOF) 1914.3 [M], HRMS C84H 139N25022S 2 
requires 19 15.00462, found 1915.00995; hplc (column 4, 5.Oml loop) R t=19minutes. 
Synthesis of 1-8.aua. 100-114 hNGF 
	
(13) 
S'.S.S.H.P.I.F.H 8 .aua.R'°°.F.I.R.1.D.T.A.C.V.C.V.L.S.R" 4 
The synthesis of the first half of this peptide as far as His 8 was carried out 
exactly as for (8/2). After coupling of Fmoc-aminoundecanoic acid, the resin-peptide 
was returned to the reaction vessel of the peptide synthesiser and the remaining 
residues were coupled using double couple cycles with HOCt, except for the two His 
residues which were coupled using double couple HOBt cycles. The cysteine 
residues were protected as the Acm derivatives. 
I1 
The peptide was cleaved from the resin (500mg) for three hours using 
cleavage solution B (section 3.2.4) (crude yield 300mg). The cysteine protected 
peptide was purified by preparative hplc (column 8) using a gradient of 10-50%B 
over 25minutes. The cysteine protecting groups were cleaved from the purified 
peptide (30mg) using the same procedure as for (8/2). After centrifugation the 
supernatant liquid of reduced peptide was dissolved in 50% acetic acid and purified 
by preparative hplc (column 6) using a gradient of 10-50%B over 25minutes. After 
lyophilisation 14mg of reduced peptide was obtained. Oxidation of this material was 
carried out in 5% DMSOITFA for 1 hour. The oxidation was monitored by 
analytical hplc (column 1, 5.Oml loop). After one hour the peak corresponding to the 
reduced peptide, eluting at 63%B, had dissapeared and a peak corresponding to the 
oxidised peptide eluted at 62%B. The DMSO/TFA solution was reduced to 
approximately Imi by evaporation in vacuo. The peptide solution was diluted to a 
volume of 6mls with 30% acetic acid and purification was carried Out by preparative 
hplc (column 6) using a gradient of 10-50%B over 25minutes. After lyophilisation, 
7mg of the title compound was obtained; amino acid analysis, Asp 1 1.20, Thr 1 l.1I, 
Ser4 3.7 1, Ala 1 1.11, Val22.2 1, 11e 3 3.22, Leu 1 1.15, Phe22.08, His22.00, Ar93 3.35, 
Cys2n.d.; m/z (FAB) 2829 [Mt], HRMS C 127H205N37032S 2 requires 2826.52083, 
found 2826.51047; hplc (column 4, 2.Oml loop) R L=16.5minutes. 
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Synthesis of 25-40 hNGF 
K.T.T.A.T.D.I.K.G.K.E.V.M.V.L.G 
Fmoc-Gly-resin (421mg, 0.25mmole) prepared as outlined in section 3.2.1 
was placed in a reaction vessel and the peptide was assembled using double couple 
cycles with HOCt. The peptide was cleaved from the resin (50mg) for three hours 
using cleavage solution B (section 3.2.4) (crude yield 29mg). Purification was 
carried Out by preparative hplc (column 6) using a gradient of 10-40%B over 
25minutes. After lyophilisation, 13mg of the title compound was obtained; amino 
acid analysis: Asp 1 l.00, Thr3 2.78, G1u11.12, 01Y22•17'  A1a 1 1.07, Va122.01, 
Met 1 0.85, 11e 1 1.06, Leu 1 1.01, Lys 32.87; m/z (FAB) 1692.0 [M], HRMS 
C 173H 131 N19024 S 1 requires 1690.94134, found 1690.94893; hplc (column 4, 5.Oml 
loop) R 1 16.5minutes. 
Synthesis of 100-114 hNGF with N-terminal p-hvdroxvphenvlacetic acid (15) 
p-hydroxyphenylacetic acid. R.F.I.R.I.D.T.A.C.V.C.V.L.S.R 
Fmoc-Arg-resin (550mg, 0.25mmole) prepared as outlined in section 3.2.1 
was placed in a reaction vessel and the peptide was assembled as far as Arg'°° using 
double couple cycles with HOCt. The cysteine residues were incorporated as the S-t -
butylsulphenyl derivatives. A small sample of the resin was removed and the peptide 
was cleaved for three hours using cleavage solution C (section 3.2.4). An analytical 
hplc (column 4, 2.Oml loop) recorded on the crude peptide showed a large single 
peak indicating the success of the synthesis thus far. To the remaining resin-peptide 
p-t-butoxyphenylacetic acid was coupled by symmetrical anhydride (immole) 
coupling. 
The peptide was cleaved from the resin (500mg) for three hours using 
cleavage solution C (section 3.2.4) (crude yield 190mg). Purification of the reduced 
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peptide was carried out by preparative hplc (column 8, 2.Oml loop) using a gradient 
of 10-60% B over 30 minutes. The reduced peptide (27mg) was dissolved in 5% 
DMSO/TFA (14mls) and oxidation was allowed to proceed for one hour. The 
TFA/DMSO solution was reduced to approximately 2mls by evaporation in vacuo. 
The resulting peptide solution was diluted to 12mls with 30% acetic acid and 
purification was carried out by preparative hplc (aquapore C 18 , 5.Oml loop) using a 
gradient of 10-50% B over 28 minutes. After lyophilisation, 8mg of the title 
compound was obtained; amino acid analysis: Asp 1 1.26, Thr1 1.07, Ser 1 1.08, 
A1a 1 1.10, Va12 1.51, 1le22.44, Leu 1 0.84, Phe 1 l.17, Ar93 3.19, Cys2n.d.; m/z (TOF) 
1883.2 [Mt], (FAB) 1884.0 [M], HRMS C 83H 135N24022S 2 requires 1885.97807, 
found 1885.97502; hplc (column 4, 2.Oml loop) R=16minutes. 




Fmoc-Arg-resin (550mg, 0.25mmole) prepared as outlined in section 3.2.1, 
was placed in a reaction vessel and the peptide was assembled using double couple 
cycles with HOCt. The cysteine residues were incorporated as the S-t-butylsulphenyl 
derivatives. 
The peptide was cleaved from the resin (400mg) for three hours using 
cleavage solution C (section 3.2.4) (crude yield 190mg). Purification of the reduced 
peptide was carried Out by preparative hplc (column 8) using a gradient of 10-60% B 
over 28 minutes. Oxidation of the purified peptide (15mg) was carried out in 5% 
DMSO/TFA (lOmis) for one hour. This was repeated on a further 12mg of reduced 
peptide. The DMSOiTFA solution in each case was reduced to approximately 1.5m1 
by evaporation in vacuo. The resulting peptide solutions were diluted to lOmis using 
20% acetic acid and purification was carried out by preparative hplc (column 6) 
using a gradient of 10-55% B over 25 minutes. After lyophilisation, 12mg of the title 
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compound was obtained; amino acid analysis: Asp 1 1.27, Thr 1 l.11, Ser 1 1.13, 
Ala1 l.08, Va12 1.54, 11e22.36, Leu 1 0.98, Phe 1 1.20, Ar932.94, Cys2n.d.; m/z (TOF) 
1751.6 [M], (FAB) 1751.9 [Mt], HRMS C75H 128N24020S 2 requires 1751.94129, 
found 1751.93876; hplc (column 4, 2.Oml loop) R 1=14.5 minutes. 




Fmoc-Gly-resin (400mg, 0,25mmole) prepared as outlined in section 3.2.1 
was placed in a reaction vessel and the peptide was assembled using double couple 
cycles with HOCt. After coupling Val" half of the resin was removed and the 
remainder was used for the synthesis of (18) below. 
The peptide was cleaved from the resin (200mg) for three hours using 
cleavage solution B (section 3.2.4). Purification of the crude peptide (30mg) was 
carried out by preparative hplc (column 6) using a gradient of 0-20% B over 10 
minutes. After lyophilisation, 20mg of the title compound was obtained; amino acid 
analysis: Thr, 1.02, Ser 1 0.7 1, Gly 1.14, Ala 1 1.09, Val,0.96, Leu 1 0.96, Lys, 1.03, 
Ar932.83; m/z (TOF) 1140.1 [M], (FAB) 1143.4, HRMS C47H90N200 13 requires 
1143.70745, found 1143.71043; hplc (column 4, 2.Oml loop) R=10 minutes. 




The remaining resin from synthesis (17) was used to assemble this peptide. 
The coupling of each residue from Cys"° to Lys 95 were carried out using double 
couple cycles with HOCt. The cysteine residues were incorporated as the S-r-
butylsulphenyl derivatives. 
The peptide was cleaved from the resin (200mg) for three hours using 
cleavage solution C (Section 3.2.4) (crude yield 95mg). Purification of the reduced 
peptide was carried out by preparative hplc (column 8) using a gradient of 10-50% B 
over 28 minutes. After lyophilisation, 32.5mg of the title compound was obtained; 
amino acid analysis: Asp 1 1.06, Thr2 l.92, Ser 1 0.97, G1n 1 1.09, G1y 1 1.08, Ala44.07, 
Va122.07, 1le22.12, Leu 1 0.99, Phe 1 l.05, Lys22.02, Arg55.46, Cys2n.d.; m/z (TOF) 
3004.8 [Mt], HRMS C130H222N45033 S 2 requires 3007.66300, found 3007.67497; 
hplc (column 4, 5.Oml loop) R 1=20minutes. 
Synthesis of 95-120 mNGF dimer 
	
(18/2) 
15mg of 95-120 mNGF reduced, prepared as explained in (18) was dissolved 
in a 50mmolar solution of ammonium acetate (150mls). The pH was adjusted to 8.5 
using ammonia. The formation of the dimer was monitored by analytical hplc 
(column 4, 2.Oml loop) over 72 hours. During this time the peak which corresponded 
to the reduced material (eluting at 52% B) decreased, while the peak corresponding 
to the dimer formed (eluting at 50%B) increased. The reaction was I stopped and the 
ammonium acetate was removed by freeze-drying. Purification was carried Out by 
preparative hplc (column 7) using a gradient of 10-40% over 22 minutes. After 
lyophilisation, 5.0mg of the title compound was obtained; amino acid analysis: 
Asp 1 l.06, Thr2 l.92, Ser 1 0.97, G1n 1 1.08, 01YI1•08.  A1a44.07, Va122.07, 11e22.12, 
Leu 1 0.99, Phe 1 1.05, Lys22.02, Arg55.46, Cys 2n.d.; m/z (TOF) 6009.8 [M], 
C260H440N90066 S 4 requires 6015.22, hplc (column 4, 2.Oml loop) R=15minutes. 
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Synthesis of 50-70.aua. 100- 114 hNGF 	 (19) 
K50.Q.Y.F.F.E.T.K.C.R.D.P.N.P.V.D.S.G.C.R.G 70.aua.R'°°.F.I.R.J.D.T.A.C.V.C.V. 
Fmoc-Arg-resin (520mg, 0.25mmole) prepared as outlined in section 3.2.1 
was placed in a reaction vessel and the peptide was assembled as far as G1y 70 using 
the same procedure as for (8/2). Following the manual coupling of Fmoc-
aminoundecanoic acid the resin-peptide was returned to the peptide synthesiser and 
the remaining residues were coupled using double couple HOCt cycles. Cys 58 . 108 
were incorporated as the S-t-butylsulphenyl derivatives. Cys 68"0  were incorporated 
as the phenylacetamidomethyl derivatives. 
The peptide was cleaved from the resin (500mg) for 5 hours using cleavage 
solution C (section3.2.4) (crude yield 300mg). An analytical hplc recorded (column 
2.Oml loop) showed the main peak to elute at 62% B. Purification of the reduced 
peptide (Cys 58 . 108  unprotected, Cys 68"0  protected) was carried out by preparative 
hplc (column 9, 5.Oml loop) using a gradient of 10-30% B over 6 minutes followed 
by 30-36% B over 12 minutes. After lyophilisation, 38mg of reduced peptide was 
obtained; m/z (TOF) 4660.6 [Mt], C 209H327 N58055 S 4 requires 4660.58; hplc (column 
5.Oml loop) R=21minutes. 
An attempted oxidation of Cys 58 to Cys' 08 was carried out by dissolving 
15mg of the reduced peptide in 5% DMSO/TFA .(20mls). The oxidation was 
followed by analytical hplc (column 4, 5.Oml loop). After 60 minutes the retention 
time of the peptide had changed from 21 minutes for the reduced peptide to 19 
minutes for the oxidised peptide. The DMSO/TFA solution was then reduced to 
approximately 4ml by evaporation in vacuo. The resulting peptide solution was 
diluted to 12mls with 30% acetic acid and purification was carried out by preparative 
hplc (column 9) using a gradient of 10-40% B over 18 minutes. After lyophilisation, 
4mg of pure peptide was obtained. On analysis it was found that the mass of the 
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product obtained indicated that the protecting groups on Cys 68 and Cys' 1 ° were 
unexpectedly cleaved during the oxidation of Cys 58 to Cys 108 . Both disulphides had 
therefore been formed at the same time; amino acid analysis: Asn/Asp 44.34, 
Thr2 1.92, Ser2 1.95, Glu/G1n22.33, Pr022.26, G1y2 1.99, Ala 1 1.05, Val 3 3.02, 11e22.07, 
Leu 1 l.04, Tyr 1 0.78, Phe32.84, Lys2 1.92, Arg54.99, Cys2n.d.; m/z (TOF) 4358.1 
[Mt], (FAB) 4363 [Mt], HRMS C 191 H3 N56053S4 requires 4361.18426 found 
4361.14491; hplc (column 4, 5.Oml loop) R 1=19.Ominutes; Ellman's test was 
negative. 
Selective oxidation of Cvs-CvsM in 50-70,aua.100-114 NGF 	(19/2) 
The remaining 500mg of peptide-resin was cleaved as outlined above. 
Purification of the reduced peptide (Cys 58" 08 deprotected, Cys68.110  still protected) 
was carried out by preparative hplc using the same conditions as mentioned above. 
After lyophilisation 35mg of the reduced compound was obtained. 
The reduced peptide (45mg, combined from both syntheses) was dissolved in 
6M GdmCl (900m1) to make a solution of 1x10 5 M concentration. Glutathione 
reduced (304mg, 1.1mM) and oxidised (60mg, 0.11mM) were added. The reaction 
was allowed to stir overnight at 4 0C. The oxidation was monitored by analytical hplc 
(column 4, 5.Oml loop). After 24 hours the retention time of the peptide had changed 
from 20.5 minutes to 20 minutes. The solution was dialysed overnight at 4 0C, using 
Spectrapor membrane tubing, molecular weight cut off 2000. This reduced the 
concentration of GdmCl in solution. Purification by preparative hplc (column 10) to 
remove the remaining GdmCl was carried out. After lyophilisation, 10mg of the title 
compound was obtained; amino acid analysis: Asn/Asp 44.34, Thr2 l.92, Ser2 l.95, 
Glu/G1n22.33, Pr022.26, G1y2 1.99, A1a 1 1.05, Va1 33.02, 11e22.07, Leu 1 l.04, Tyr 1 0.78, 
Phe3 2.84, Lys2 1.92, Ar9 54.99, Cys 4 n.d.; m/z (TOF) 4658 [Mt], (FAB) 4655 [Mt], 
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FIRMS C 0 11325N58055S4 requires 4658.34456 found 4658.32495; hplc (column 4, 
5.Oml loop) R=20minutes. 





Fmoc-Arg-resin (507mg, 0.25mmole) prepared as outlined in section 3.2.1 
was placed in a reaction vessel and the peptide was assembled using double couple 
cycles with HOCt. Fmoc- 1 -amino-4-carboxy-cyclopentane was coupled manually by 
preparing the HOBt ester (immole) and sonicating overnight with the peptide-resin. 
The peptide was cleaved from the resin (200mg) for 3 hours in 
90%TFA/5%H20/5%EDT (lOmis) (crude yield 85mg). The peptide (25mg) was 
purified by preparative hplc (column 8) using a gradient of 10-60% over 28 minutes. 
After lyophilisation, 17.5mg of the title compound was obtained; amino acid 
analysis; Asp 1 1.11, Thr 1 0.97, Ser 1 0.99, A1a 1 0.99, Va1 1 0.90, 11e2 1.96, Leu 1 1.15, 
Phe 1 0.99, Ar932.90; m/z (TOF) 1558.7 [M], (FAB) 1558.0 [Mt], HRMS 
C70H 120N220 18 requires 1557.92292 found 1557.927 14; hplc (column 5, 5.Oml loop) 
R=20 minutes. 





Fmoc-Arg-resin (550mg, 0.25mmole) was placed in a reaction vessel and the 
peptide was assembled using double couple cycles (symmetrical anhydride coupling 
followed by HOBt coupling). Extended coupling times were used from Cys"° to 
Arg'°°. After coupling Val", half of the resin was removed and stored for the 
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symthesis of compound (21). Fmoc-aminoundecanoic acid was coupled manually as 
for (8/2). Cys' 10 ' 68 were incorporated as the phenylacetamidomethyl derivatives. 
Cys 108,58  were incorporated as the S-t-butylsulphenyl derivatives. 
The peptide was cleaved from the resin (500mg) for 5 hours using cleavage 
solution C (section 3.2.4) (crude yield 210mg). The reduced peptide (120mg, 
Cys 108 '58 unprotected, Cys"°. 68 still protected) was purified by preparative hplc 
(column 9) using a gradient of 10-30% over 6 minutes followed by 30-40% over 20 
minutes. After lyophilisation, 20.5mg of pure, reduced peptide was obtained. 
Cleavage of the protecting groups on Cys 110 .68 and the formation of both 
disulphides was carried out by dissolving the reduced peptide (10mg) in 5% 
DMSO/TFA (lOmis). The reaction was allowed to stir for one hour. The oxidation 
was monitored by analytical hplc (column , 4, 2.Oml loop). As the oxidation 
proceeded the retention time of the peptide changed from 17 minutes to 16 minutes. 
The DMSOIFFA solution was reduced to 2m1 by evaporation in vacuo. The resulting 
peptide solution was diluted to lOmis using 30% acetic acid. Purification of the 
peptide was carried out by preparative hplc (column 7) using a gradient of 10-60% B 
over 30 minutes. After lyophilisation, 3.5mg of the title compound was obtained; 
amino acid analysis: Asn/Asp 22.52, Thr22.22, Ser3 3.15, Glu/G1n 43.97, Pro 1 l.21, 
G1y22.19, A1a2 1.69, Va1 32.74, Ile2 l.49, Leu 1 0.93, Tyr 1 0.76, Phe32.95, Lys 1 1.22, 
Ar966.62, Cys 4 n.d.; m/z (TOF) 4350.4 [Mt], (FAB) 4348 [Mt], HRMS 
C 189H304N58052S 4 requires 4349.19549 found 4349.19481; hplc (column 4, 5.Oml 
loop) R=19  minutes. 
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Synthesis of 1-8.aua.100-114 mNGF 
	
(21) 
S'.S.T.H.P.V.F.H8.aua.R 100.F.I.R.I.D.T.A.C.V.C.V.L.S.R" 4 
The second half of the resin which was removed from the synthesis of 
compound (22) was placed in a reaction vessel and the peptide was assembled as far 
as His8 using the same procedure as for compound (22). Coupling of His 8 to Ser' 
was carried out using double couple cycles (symmetrical anhydride followed by 
HOBt coupling) with standard coupling times. The cysteine residues were 
incorporated as the S-t-butylsulphenyl derivatives. 
The peptide was cleaved from the resin (300mg) for 3 hours using 
90%TFA/5%H20/5%EDT (crude yield 210mg). The cysteine protecting groups 
were cleaved from the crude peptide (80mg) for 5 hours using the same procedure as 
for (2). The cleavage was monitored by analytical hplc (column 4, 2.Oml loop). The 
retention time of the peptide changed from 18.5 minutes to 17 minutes as the 
deprotection proceeded (yield 75mg). The crude dithiol peptide (15mg) was 
dissolved in 5% DMSOITFA (10mls) and oxidation was allowed to proceed for one 
hour. The DMSO/TFA solution was then reduced to approximately 2mls by 
evaporation in vacuo. The resulting peptide solution was diluted to lOmls with 30% 
acetic acid. Purification by preparative hplc (column 7) using a gradient of 10-60% 
over 28 minutes. After lyophilisation, 4mg of the title compound was obtained; 
amino acid analysis: Asp 1 l.16, Thr22.06, Ser32.74, Pro 1 1.16, Ala 1 l.45, Va13 2.9, 
1le22.5, Leu 1 l.36, Phe22.25, His22.11, Ar93 3.15, Cys2n.d. m/z (TOF) 2828.4 [Mt], 
(FAB) 2827 [Mt], HRMS C 127H205 N37032S 2 requires 2827.51829, found 
2827.53432; hplc (column 4, 5.Oml loop) R 1=l9minutes. 
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This peptide was synthesised and cleaved from the resin by Alan 
Cuthbertson( 126). An analytical hplc (column 4, 5.Oml loop) was recorded of the 
crude material available (178mg). This showed the main peak eluting at 65% B. 
Purification of the crude peptide (80mg) was carried out by preparative hplc (column 
6) using a gradient of 10-36% B over 14 minutes. After lyophilisation, 6.0mg of the 
title compound was obtained; amino acid analysis: Asn/Asp 32.96, Ser 1 0.82, 
Pr022.14, Gly 1 l.03, Val 1 l.04, Arg 1 0.99; m/z (FAB) 957 [M], HRMS C38H61 N 130 16 
requires 956.44375 found 956.45032; hplc (column 4, 5.Oml loop) R=20minutes. 




This peptide was synthesised and cleaved from the resin by Alan 
Cuthbertson( 126). An analytical hplc (column 4, 5.Oml loop) was recorded of the 
crude material available (114mg). This showed the main peak eluting at 63% B. 
Purification of the crude peptide (20mg) was carried Out by preparative hplc (column 
6) using a gradient of 10-45% B over 15 minutes. After lyophilisation, 10mg of the 
title compound was obtained; amino acid analysis: Asn 1 0.89, Ser 1 0.87, G1n 1 1.20, 
Val 1 1.08, Tyr 1 0.93, Phe32.98, Lys 1 l.01; m/z (FAB) 1178 [M]; HRMS 
C59H78N 120 14 requires 1179.58387 found 1179.58217; hplc (column 4, 5.Oml loop) 
R= 1 9minutes. 
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This peptide was synthesised and cleaved from the resin by David 
Tumelty(127). An analytical hplc (column 1, 2.Oml loop) was recorded of the crude 
peptide available (180mg). This showed a single peak eluting at 40% B with a 
smaller peak eluting at 45% B. Purification of the crude peptide (50mg) by 
preparative hplc (column 6) was carried Out using a gradient of 10-25% B over 15 
minutes. After lyophilisation, 22mg of the title compound was obtained; amino acid 
analysis: Thr 1 1.07, Glu22.13, A1a 1 0.91, Val3 2.77, Leu 1 l.00, Lys 1 1.09; m/z (FAB) 
987 [M], HRMS C44H78N 10015 requires 987.57264 found 987.57279; hplc (column 
1, 2.Oml loop) R 1=llminutes. 




This peptide was synthesised and cleaved from the resin by David 
Tumelty(127). An analytical hplc (column 2, 2.Oml loop) was recorded of the crude 
peptide available (400mg). The main peak eluted at 43% B. Purification of the crude 
peptide (30mg) was carried out by preparative hplc (column 6) using a gradient of 
10-35% B over 25 minutes. After lyophilisation, 10mg of the title compound was 
obtained; amino acid analysis: Asp 1 1.03, Thr 1 1.05, Glu/G1n 22.16, Tyr 1 1.01, 
Phe22.11, Lys22.09, Arg 1 1.09; m/z (FAB) 1463.7 [M], HRMS C66H97N 17019 
requires 1464.69456 found 1464.70087 ; hplc (column 2, 2.Oml loop) R=13minutes. 
APPENDIX 1 
The nitrogen bubbler apparatus for the manual synthesis of peptides. The resin-
peptide is contained within the cylindrical reaction vessel and is agitated with 
nitrogen. Reagents are added manually from the top and removed under suction 


























hNGF8107 	TTTHTFVKALTMDG KQAAWRFIRIDTA 
mNGF9520 	KQAAWRFIRIDTAC(H)VC(H)VLSRK 
ATRRG 
mNGF9520 	dimer through disulphides 
SSSHPIFHauaRFIRIDTACVCVLSR (oxid) 
mNGF 8 ' 14 SSTHPVFHauaRFIRIDTACVCVLSR (oxid) 
NGF3234 '95"00114  KGKauaKauaRFIRIDTACVCVLSR (oxid) 
NGF3234 '95' 100414 KG KauaKauaRFIRIDTAC(Acm)V 
C(Acm)VLSR 
NGF3234 '95' 100 KG KauaKauaR 




hNGF5070"00114  KQYFFETKCRDPNPVDSGC(phAcm)R 
GauaRFIRIDTACVC(phAcm)VLS (oxid) 
RFIRIDTACVCVLSR (oxid) 
NGF1004; Cha 101 RChaIRIDTACVCVLSR (oxid) 
NGF100114 ; Tyr' 01 RYIRIDTACVCVLSR (oxid) 
NGF1004 ; 0rn 100 OFIRIDTACVCVLSR (oxid) 
NGF100414 ; Lys'°° KFIRIDTACVCVLSR (oxid) 
p-hydroxyphenylacetic acid-NGF 100114 























































(bold = human or conserved mouse and human sequence; other = mouse sequence) 
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The following list of peptides were synthesised by Alan Cuthbertson( 126) and David 
Tumelty(127) and tested on the p75 assay. All sequences are conserved human and 
mouse except those specifically marked as hNGF. 
p75 assay 
Amino Acid Sequence  
NGF'° 17 GEFSVCDS 
NGF1523 CDSVSVWVG 
NGF1428 VCDSVSVWVGDKTTA-NU2 
NGF1428 Ac-VCDSVSVWVGDKTTA-NH 2 
NGF1428 VSDSVSVWVGDKTTA-NH 2 
NGF1428 Ac-VSDSVSVWVGDKTTA-NH 2 
NGF1922 SVWV 
hNGF1922 Ac-SVWV 
NGF21-36 WVGDKTTATDIKG KEY 








NGF749 ' KHWNSYCTTTHTFVKALT 




hNGF95120 Cys' 08 S-t-butyl, Cys"° Acm 
hNGF95120 Cys 110Acm 
hNGF95120 oxidised 
NGF95 " KQAAWRFIRIDTACVCVLSRKA (oxid) 
NCJF95416 reduced 
NGF95105 KQAAWRFIRH) 































Amino Acid Sequence 
	
% Inhibition @ Xp.M 
NGF97-116 	AAWRFIRIDTACVCVLSRKA 











GIy' 11113, Cys'°8"°Acm 
G1y111113 , CyS 108"0oxid 
1-113 
RFIR!DTACVCVLSRK (oxid) 
NGF'°° 115 RFIRIDTACVCVLSR K-NH2 	(oxid) 
NGF100115  RFIRIDTACVCVLSRK-NH-heptyl (oxid) 
NGF100115 RFIRIDTACCVLSRK(oxid) 
NGF'°° 115  RFIRIDTACCVLSRK(reduced) 





















RFIRIDTAPenVPenVLSR 	(oxid) -24@lOjiM 
RFRIDTAPenVPenVLSR di-Acm protected -26@lOjIM 
(cyclised by lactam bridge between Asp 105 side chain and N-terminus) 
Cys 108"°Acm 4@10iM 
D-Leu 102 	(oxid) 38@10J.LM 
D-11e 104 (oxid) 15@10j.tM 
D-Va1 111 	(oxid) 21@10p.M 
D-Va1 109 ' 111 (oxid) (10 50 12.5) 
Aib 109 	(oxid) 23@10iM 
Aib 108 	(oxid) 70@l0.tM 
Aib 1 	(oxid) 27t10tM 
NIe 3 	(oxid) (!C 50 1.2) 
N1e 106 ' 113 	Cys 108" 10Acm 44@10tM 
RFIRIDTACVCVLS 	(oxid) 2330iiM 
RFIRIDTACVC 	(oxid) 30@100jiM 
reduced 0@100M 
FIRIDTACVCVLSRK 	(oxid) 31@30jtM 











NGF'° 1 "5 
NGF'°3 "6 
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Amino Acid Sequence 
NGF106116 	TACVCVLSRKA (oxid) 
NGF106116 	reduced 
NGF111-116 	VLSRKA 
hNGF50-70 ' 95-120 KQYFFETKCRDPNPVDSGCRGGGGGQAA 
WRFIRIDTACVCVLSRKAVRRA 
(Cys58"08 S-t-butyl, Cys 68" 10Acm) 
hNGF5070 ' 95120 Cys58"08 oxid, Cys68" 10Acm 
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